

Andreas von Deimling

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5202317/publications.pdf>

Version: 2024-02-01

716
papers

91,829
citations

466

130
h-index

402

278
g-index

735
all docs

735
docs citations

735
times ranked

59660
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Dysfunctional dendritic cells limit antigen-specific T cell response in glioma. <i>Neuro-Oncology</i> , 2023, 25, 263-276. | 1.2 | 23 |
| 2 | Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis. <i>Gut</i> , 2022, 71, 391-401. | 12.1 | 21 |
| 3 | Fibroblast Activation Proteinâ€“Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 127-133. | 5.0 | 72 |
| 4 | Mucosal melanomas of different anatomic sites share a common global <scp>DNA</scp> methylation profile with cutaneous melanoma but show locationâ€“dependent patterns of genetic and epigenetic alterations. <i>Journal of Pathology</i> , 2022, 256, 61-70. | 4.5 | 12 |
| 5 | Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics. <i>Neuro-Oncology</i> , 2022, 24, 571-581. | 1.2 | 39 |
| 6 | Primary central nervous system sarcoma with <i>DICER1</i> mutationâ€“treatment results of a novel molecular entity in pediatric Peruvian patients. <i>Cancer</i> , 2022, 128, 697-707. | 4.1 | 14 |
| 7 | Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study. <i>Clinical Cancer Research</i> , 2022, 28, 116-128. | 7.0 | 8 |
| 8 | T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas. <i>Clinical Cancer Research</i> , 2022, 28, 378-389. | 7.0 | 11 |
| 9 | DNA methylation-based classification of malformations of cortical development in the human brain. <i>Acta Neuropathologica</i> , 2022, 143, 93-104. | 7.7 | 18 |
| 10 | Intracranial mesenchymal tumors with FETâ€“CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomas. <i>Brain Pathology</i> , 2022, 32, e13037. | 4.1 | 11 |
| 11 | Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. <i>Acta Neuropathologica Communications</i> , 2022, 10, 5. | 5.2 | 12 |
| 12 | Prognostic impact of genetic alterations and methylation classes in meningioma. <i>Brain Pathology</i> , 2022, 32, e12970. | 4.1 | 27 |
| 13 | DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcomeâ€“including in elderly patients. <i>Acta Neuropathologica Communications</i> , 2022, 10, 39. | 5.2 | 6 |
| 14 | Rapid-CNS2: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study. <i>Acta Neuropathologica</i> , 2022, 143, 609-612. | 7.7 | 19 |
| 15 | Cellular context determines <scp>DNA</scp> methylation profiles in <scp>SWI</scp>/<scp>SNF</scp>-deficient cancers of the gynecologic tract. <i>Journal of Pathology</i> , 2022, 257, 140-145. | 4.5 | 9 |
| 16 | Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease. <i>Neuro-Oncology</i> , 2022, 24, 1689-1699. | 1.2 | 11 |
| 17 | Adult cerebellar glioblastoma categorized into a pediatric methylation class with a unique radiological and histological appearance: illustrative case. <i>Journal of Neurosurgery Case Lessons</i> , 2022, 3, . | 0.3 | 0 |
| 18 | Methylation classifiers: Brain tumors, sarcomas, and what's next. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 346-355. | 2.8 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial. Clinical Cancer Research, 2022, 28, 2527-2535. | 7.0 | 27 |
| 20 | A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era. Cancer Discovery, 2022, 12, 331-355. | 9.4 | 70 |
| 21 | Oligosarcomas, IDH-mutant are distinct and aggressive. Acta Neuropathologica, 2022, 143, 263-281. | 7.7 | 18 |
| 22 | Osteosarcoma: Novel prognostic biomarkers using circulating and cell-free tumour DNA. European Journal of Cancer, 2022, 168, 1-11. | 2.8 | 8 |
| 23 | Endometrial Stromal Sarcomas With BCOR Internal Tandem Duplication and Variant BCOR/BCORL1 Rearrangements Resemble High-grade Endometrial Stromal Sarcomas With Recurrent CDK4 Pathway Alterations and MDM2 Amplifications. American Journal of Surgical Pathology, 2022, 46, 1142-1152. | 3.7 | 10 |
| 24 | HIP1R and Vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma. Neuro-Oncology, 2022, , . | 1.2 | 4 |
| 25 | Diagnostic potential of extracellular vesicles in meningioma patients. Neuro-Oncology, 2022, 24, 2078-2090. | 1.2 | 6 |
| 26 | OTHR-41. Amplification of the PLAG family genes “ PLAGL1 and PLAGL2 “ is a key feature of a novel embryonal CNS tumor type. Neuro-Oncology, 2022, 24, i156-i156. | 1.2 | 1 |
| 27 | MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i107-i107. | 1.2 | 1 |
| 28 | OTHR-32. The Pediatric Targeted Therapy 2.0 registry: robust molecular diagnostics for precision oncology. Neuro-Oncology, 2022, 24, i154-i154. | 1.2 | 0 |
| 29 | LGG-17. Preventing recurrence: targeting molecular mechanisms driving tumor growth rebound after MAPKi withdrawal in pediatric low-grade glioma. Neuro-Oncology, 2022, 24, i91-i91. | 1.2 | 0 |
| 30 | LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma. Neuro-Oncology, 2022, 24, i91-i92. | 1.2 | 0 |
| 31 | LGG-14. LOGGIC (Low Grade Glioma in Children) Core BioClinical Data Bank: Establishment and added clinical value of an international molecular diagnostic registry for pediatric low-grade glioma patients. Neuro-Oncology, 2022, 24, i90-i90. | 1.2 | 1 |
| 32 | DNA-methylome-assisted classification of patients with poor prognostic subventricular zone associated IDH-wildtype glioblastoma. Acta Neuropathologica, 2022, 144, 129-142. | 7.7 | 5 |
| 33 | MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy “ Results of the MET-HIT2000-BIS4 trial. Neuro-Oncology, 2022, 24, i104-i104. | 1.2 | 1 |
| 34 | AAMP is a binding partner of costimulatory human B7-H3. Neuro-Oncology Advances, 2022, 4, . | 0.7 | 4 |
| 35 | Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression. Acta Neuropathologica, 2022, 144, 339-352. | 7.7 | 5 |
| 36 | The molecular evolution of glioblastoma treated by gross total resection alone. Neuro-Oncology, 2021, 23, 334-336. | 1.2 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. <i>Acta Neuropathologica</i> , 2021, 141, 85-100. | 7.7 | 52 |
| 38 | EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 170-186. | 27.6 | 826 |
| 39 | Accurate calling of <i>KIAA1549</i> – <i>BRAF</i> fusions from DNA of human brain tumours using methylation array-based copy number and gene panel sequencing data. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 406-414. | 3.2 | 12 |
| 40 | A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of <i>EGFR</i> . <i>Neuro-Oncology</i> , 2021, 23, 34-43. | 1.2 | 75 |
| 41 | Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with <i>FOXR2</i> -activation. <i>Acta Neuropathologica Communications</i> , 2021, 9, 20. | 5.2 | 23 |
| 42 | Integrated molecular analysis of adult sonic hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with <i>VEGFA</i> as potent prognostic indicator. <i>Neuro-Oncology</i> , 2021, 23, 1576-1585. | 1.2 | 7 |
| 43 | G3BPs tether the TSC complex to lysosomes and suppress mTORC1 signaling. <i>Cell</i> , 2021, 184, 655-674.e27. | 28.9 | 65 |
| 44 | Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma. <i>Nature Communications</i> , 2021, 12, 1014. | 12.8 | 81 |
| 45 | The age of adult pilocytic astrocytoma cells. <i>Oncogene</i> , 2021, 40, 2830-2841. | 5.9 | 6 |
| 46 | A vaccine targeting mutant IDH1 in newly diagnosed glioma. <i>Nature</i> , 2021, 592, 463-468. | 27.8 | 232 |
| 47 | Telomerase reverse transcriptase promoter mutation and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase wild-type glioblastoma: is there a link?. <i>European Journal of Cancer</i> , 2021, 147, 84-94. | 2.8 | 10 |
| 48 | Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid in patients with brain malignancies. <i>Journal of Neurochemistry</i> , 2021, 158, 522-538. | 3.9 | 18 |
| 49 | Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtype. <i>Acta Neuropathologica</i> , 2021, 141, 971-974. | 7.7 | 12 |
| 50 | Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1. <i>Acta Neuropathologica</i> , 2021, 142, 179-189. | 7.7 | 24 |
| 51 | Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. <i>Neuro-Oncology</i> , 2021, 23, 1547-1559. | 1.2 | 34 |
| 52 | Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial Ependymomas. <i>Cancer Discovery</i> , 2021, 11, 2230-2247. | 9.4 | 39 |
| 53 | Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct <i>DICER1</i> -associated subgroup. <i>Modern Pathology</i> , 2021, 34, 1558-1569. | 5.5 | 28 |
| 54 | Deep Neural Network for Differentiation of Brain Tumor Tissue Displayed by Confocal Laser Endomicroscopy. <i>Frontiers in Oncology</i> , 2021, 11, 668273. | 2.8 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. <i>Nature Cancer</i> , 2021, 2, 723-740. | 13.2 | 110 |
| 56 | Loss of H3K27me3 in meningiomas. <i>Neuro-Oncology</i> , 2021, 23, 1282-1291. | 1.2 | 45 |
| 57 | DNA methylation-based profiling of bone and soft tissue tumours: a validation study of the DKFZ Sarcoma Classifier™. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 350-360. | 3.0 | 25 |
| 58 | The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. <i>Neuro-Oncology</i> , 2021, 23, 1231-1251. | 1.2 | 4,534 |
| 59 | EMBR-21. CLINICALLY TRACTABLE OUTCOME PREDICTION OF GROUP 3/4 MEDULLOBLASTOMA BASED ON TPD52 IMMUNOHISTOCHEMISTRY: A MULTICOHORT STUDY. <i>Neuro-Oncology</i> , 2021, 23, i10-i10. | 1.2 | 0 |
| 60 | Myxoid pleomorphic liposarcoma—a clinicopathologic, immunohistochemical, molecular genetic and epigenetic study of 12 cases, suggesting a possible relationship with conventional pleomorphic liposarcoma. <i>Modern Pathology</i> , 2021, 34, 2043-2049. | 5.5 | 24 |
| 61 | Molecular characterisation of sporadic endolymphatic sac tumours and comparison to von Hippel-Lindau disease-related tumours. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 756-767. | 3.2 | 2 |
| 62 | Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. <i>Neuro-Oncology</i> , 2021, 23, 1597-1611. | 1.2 | 22 |
| 63 | EPCT-06. PRECISION ONCOLOGY IN THE PEDIATRIC TARGETED THERAPY 2.0 PROGRAM. <i>Neuro-Oncology</i> , 2021, 23, i47-i48. | 1.2 | 0 |
| 64 | EPEN-03. ZFTA/C11ORF95 FUSIONS DRIVE SUPRATENTORIAL EPENDYMOMA VIA SHARED ONCOGENIC MECHANISMS. <i>Neuro-Oncology</i> , 2021, 23, i13-i14. | 1.2 | 1 |
| 65 | Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23. <i>Cancers</i> , 2021, 13, 3451. | 3.7 | 8 |
| 66 | Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature. <i>Modern Pathology</i> , 2021, 34, 2122-2129. | 5.5 | 17 |
| 67 | 68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas—Imaging analysis and histological validation. <i>Radiotherapy and Oncology</i> , 2021, 160, 192-201. | 0.6 | 40 |
| 68 | Molecular diagnostics in drug-resistant focal epilepsy define new disease entities. <i>Brain Pathology</i> , 2021, 31, e12963. | 4.1 | 13 |
| 69 | DNA Methylation Profiling Discriminates between Malignant Pleural Mesothelioma and Neoplastic or Reactive Histologic Mimics. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 834-846. | 2.8 | 7 |
| 70 | Intrathecal activation of CD8 ⁺ memory T cells in IgG4-related disease of the brain parenchyma. <i>EMBO Molecular Medicine</i> , 2021, 13, e13953. | 6.9 | 6 |
| 71 | PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. <i>Acta Neuropathologica</i> , 2021, 142, 841-857. | 7.7 | 36 |
| 72 | Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. <i>Acta Neuropathologica</i> , 2021, 142, 827-839. | 7.7 | 33 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. <i>Cancer Discovery</i> , 2021, 11, 2764-2779. | 9.4 | 110 |
| 74 | Subgroup and subtype-specific outcomes in adult medulloblastoma. <i>Acta Neuropathologica</i> , 2021, 142, 859-871. | 7.7 | 34 |
| 75 | Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. <i>Nature Communications</i> , 2021, 12, 5530. | 12.8 | 24 |
| 76 | Comparative evaluation of T cell receptors in experimental glioma-draining lymph nodes. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab147. | 0.7 | 1 |
| 77 | GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. <i>Acta Neuropathologica</i> , 2021, 142, 1065-1069. | 7.7 | 16 |
| 78 | Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498. | 12.8 | 237 |
| 79 | Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma. <i>Theranostics</i> , 2021, 11, 9217-9233. | 10.0 | 16 |
| 80 | Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. <i>Acta Neuropathologica</i> , 2021, 141, 281-290. | 7.7 | 31 |
| 81 | The anesthetist's choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients. <i>Neurosurgical Review</i> , 2021, 44, 2707-2715. | 2.4 | 9 |
| 82 | Genetic and epigenetic characterization of posterior pituitary tumors. <i>Acta Neuropathologica</i> , 2021, 142, 1025-1043. | 7.7 | 7 |
| 83 | Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. <i>Journal of Clinical Oncology</i> , 2021, 39, 3839-3852. | 1.6 | 93 |
| 84 | PATH-23. OLIGOSARCOMA, IDH-MUTANT IS A DISTINCT AGGRESSIVE TYPE. <i>Neuro-Oncology</i> , 2021, 23, vi119-vi120. | 1.2 | 0 |
| 85 | NCOG-25. REVISITING THE PIGNATTI RISK SCORE IN LOW-GRADE GLIOMA PATIENTS IN THE MOLECULAR ERA. <i>Neuro-Oncology</i> , 2021, 23, vi157-vi157. | 1.2 | 0 |
| 86 | PATH-34. MOLECULAR AND CLINICAL HETEROGENEITY WITHIN SPINAL EPENDYMOMAS. <i>Neuro-Oncology</i> , 2021, 23, vi122-vi122. | 1.2 | 0 |
| 87 | BIOM-39. METHYLATION AND MUTATION PROFILES IN MENINGIOMA CELL-DERIVED EXTRACELLULAR VESICLE DNA REFLECT EPIGENETIC AND GENOMIC ALTERATIONS IN ORIGINAL TUMORS. <i>Neuro-Oncology</i> , 2021, 23, vi19-vi19. | 1.2 | 0 |
| 88 | PATH-48. RAPID-CNS2: RAPID COMPREHENSIVE ADAPTIVE NANOPORE-SEQUENCING OF CNS TUMORS, A PROOF OF CONCEPT STUDY. <i>Neuro-Oncology</i> , 2021, 23, vi126-vi126. | 1.2 | 0 |
| 89 | PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED. <i>Neuro-Oncology</i> , 2021, 23, vi123-vi124. | 1.2 | 0 |
| 90 | PATH-46. DIAGNOSTIC IMPACT OF THE CNS TUMOR METHYLATION PROFILING IN A NEUROPATHOLOGY CONSULT PRACTICE. <i>Neuro-Oncology</i> , 2021, 23, vi125-vi126. | 1.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas. <i>Clinical Cancer Research</i> , 2020, 26, 93-100. | 7.0 | 34 |
| 92 | Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. <i>Acta Neuropathologica</i> , 2020, 139, 193-209. | 7.7 | 83 |
| 93 | Assessment of Melanin Content and its Influence on Susceptibility Contrast in Melanoma Metastases. <i>Clinical Neuroradiology</i> , 2020, 30, 607-614. | 1.9 | 9 |
| 94 | Sclerosing epithelioid mesenchymal neoplasm of the pancreas—A proposed new entity. <i>Modern Pathology</i> , 2020, 33, 456-467. | 5.5 | 10 |
| 95 | FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas. <i>Acta Neuropathologica</i> , 2020, 139, 175-192. | 7.7 | 15 |
| 96 | Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation. <i>Acta Neuropathologica</i> , 2020, 139, 403-406. | 7.7 | 9 |
| 97 | T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa004. | 0.7 | 27 |
| 98 | Machine learning workflows to estimate class probabilities for precision cancer diagnostics on DNA methylation microarray data. <i>Nature Protocols</i> , 2020, 15, 479-512. | 12.0 | 89 |
| 99 | Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. <i>Acta Neuropathologica</i> , 2020, 139, 277-286. | 7.7 | 36 |
| 100 | YAP1-fusions in pediatric NF2-wildtype meningioma. <i>Acta Neuropathologica</i> , 2020, 139, 215-218. | 7.7 | 45 |
| 101 | DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 121-130. | 5.6 | 55 |
| 102 | Clinicopathologic and molecular features of intracranial desmoplastic small round cell tumors. <i>Brain Pathology</i> , 2020, 30, 213-225. | 4.1 | 20 |
| 103 | Kaposiform hemangioendothelioma and tufted angioma – (epi)genetic analysis including genome-wide methylation profiling. <i>Annals of Diagnostic Pathology</i> , 2020, 44, 151434. | 1.3 | 16 |
| 104 | Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. <i>Acta Neuropathologica</i> , 2020, 139, 243-257. | 7.7 | 50 |
| 105 | High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma. <i>Pathology Research and Practice</i> , 2020, 216, 152728. | 2.3 | 8 |
| 106 | Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker. <i>Acta Neuropathologica</i> , 2020, 139, 583-596. | 7.7 | 13 |
| 107 | DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 97-104. | 2.5 | 29 |
| 108 | IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. <i>Cell</i> , 2020, 182, 1252-1270.e34. | 28.9 | 259 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | Mosaic trisomy of chromosome 1q in human brain tissue associates with unilateral polymicrogyria, very early-onset focal epilepsy, and severe developmental delay. <i>Acta Neuropathologica</i> , 2020, 140, 881-891. | 7.7 | 28 |
| 110 | Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. <i>Cancer Medicine</i> , 2020, 9, 8373-8385. | 2.8 | 19 |
| 111 | An activating germline IDH1 variant associated with a tumor entity characterized by unilateral and bilateral chondrosarcoma of the mastoid. <i>Human Genetics and Genomics Advances</i> , 2020, 1, 100006. | 1.7 | 3 |
| 112 | Infratentorial IDH-mutant astrocytoma is a distinct subtype. <i>Acta Neuropathologica</i> , 2020, 140, 569-581. | 7.7 | 45 |
| 113 | Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. <i>Radiology</i> , 2020, 297, 164-175. | 7.3 | 19 |
| 114 | Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report. <i>Acta Neurochirurgica</i> , 2020, 162, 3019-3024. | 1.7 | 3 |
| 115 | Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7801. | 4.1 | 8 |
| 116 | Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02. <i>Translational Oncology</i> , 2020, 13, 100852. | 3.7 | 4 |
| 117 | Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity. <i>Acta Neuropathologica</i> , 2020, 140, 893-906. | 7.7 | 19 |
| 118 | Aggressive Hematopoietic Malignancy Characterized by Biallelic Loss of SMARCB1. <i>JCO Precision Oncology</i> , 2020, 4, 1280-1284. | 3.0 | 1 |
| 119 | An optimized workflow to improve reliability of detection of KIAA1549:BRAF fusions from RNA sequencing data. <i>Acta Neuropathologica</i> , 2020, 140, 237-239. | 7.7 | 5 |
| 120 | Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. <i>Neuro-Oncology</i> , 2020, 22, 1667-1676. | 1.2 | 9 |
| 121 | Germline <i>SDHB</i> inactivating mutation in gastric spindle cell sarcoma. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 601-608. | 2.8 | 4 |
| 122 | Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines. <i>Cancers</i> , 2020, 12, 577. | 3.7 | 7 |
| 123 | CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. <i>Acta Neuropathologica</i> , 2020, 140, 409-413. | 7.7 | 116 |
| 124 | Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdz060. | 0.7 | 8 |
| 125 | Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. <i>Neuro-Oncology</i> , 2020, 22, 1162-1172. | 1.2 | 42 |
| 126 | Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. <i>Nature Communications</i> , 2020, 11, 931. | 12.8 | 112 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Interdisciplinary approach allows minimally invasive, nerve-sparing removal of retroperitoneal peripheral nerve sheath tumors. <i>Langenbeck's Archives of Surgery</i> , 2020, 405, 199-205. | 1.9 | 7 |
| 128 | Analysis of a Surgical Series of 21 Cerebral Radiation Necroses. <i>World Neurosurgery</i> , 2020, 137, e462-e469. | 1.3 | 6 |
| 129 | Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival. <i>Clinical Cancer Research</i> , 2020, 26, 2231-2243. | 7.0 | 21 |
| 130 | cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. <i>Acta Neuropathologica</i> , 2020, 139, 603-608. | 7.7 | 344 |
| 131 | Endometrial stromal sarcomas with <i>BCOR</i> rearrangement harbor <i>MDM2</i> amplifications. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 178-184. | 3.0 | 32 |
| 132 | Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113. | 1.2 | 543 |
| 133 | Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, 2028-2040. | 1.6 | 58 |
| 134 | cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. <i>Brain Pathology</i> , 2020, 30, 844-856. | 4.1 | 363 |
| 135 | Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963. | 9.4 | 157 |
| 136 | Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. <i>Journal of Clinical Investigation</i> , 2020, 130, 2488-2495. | 8.2 | 23 |
| 137 | The pediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA10503-LBA10503. | 1.6 | 12 |
| 138 | Quality assurance in neuropathology: Experiences from the round robin trials on IDH mutation and MGMT promoter methylation testing launched by the Quality Assurance Initiative Pathology (QuIP) in 2018 and 2019. <i>Journal of Neuropathology</i> , 2020, 39, 203-211. | | 3 |
| 139 | QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL. <i>Neuro-Oncology</i> , 2020, 22, iii433-iii433. | 1.2 | 0 |
| 140 | MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS. <i>Neuro-Oncology</i> , 2020, 22, iii413-iii413. | 1.2 | 0 |
| 141 | PATH-04. AN ENHANCED AI-DRIVEN PLATFORM FOR PRECISION MOLECULAR BRAIN TUMOR DIANOSTICS. <i>Neuro-Oncology</i> , 2020, 22, iii425-iii425. | 1.2 | 0 |
| 142 | PATH-26. RNA SEQUENCING OF FORMALIN-FIXED PARAFFIN-EMBEDDED SPECIMENS IN DIAGNOSTIC ROUTINE IDENTIFIES CLINICALLY RELEVANT GENE FUSIONS. <i>Neuro-Oncology</i> , 2020, 22, iii429-iii430. | 1.2 | 0 |
| 143 | LGG-33. ISOMORPHIC DIFFUSE GLIOMA HAS RECURRENT GENE FUSIONS OF MYBL1 OR MYB AND CAN BE DISTINGUISHED FROM OTHER MYB/MYBL1 ALTERED GLIOMAS BASED ON A DISTINCT MORPHOLOGY AND DNA METHYLATION PROFILE. <i>Neuro-Oncology</i> , 2020, 22, iii372-iii373. | 1.2 | 0 |
| 144 | EPEN-18. CROSS-SPECIES GENOMICS IDENTIFIES GLI2 AS AN ONCOGENE OF C11orf95 FUSION-POSITIVE SUPRATENTORIAL EPENDYMOMA. <i>Neuro-Oncology</i> , 2020, 22, iii311-iii311. | 1.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | MBCL-06. RISK STRATIFICATION IMPROVEMENT OF THE HIT2000 AND I-HIT-MED COHORTS USING MOLECULAR SUBTYPES I-VIII OF GROUP 3/4 MEDULLOBLASTOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii388-iii388. | 1.2 | 0 |
| 146 | MBRS-68. SINGLE NUCLEUS RNA-SEQUENCING DECIPHERS INTRATUMORAL HETEROGENEITY IN MEDULLOBLASTOMA WITH EXTENSIVE NODULARITY (MBEN). <i>Neuro-Oncology</i> , 2020, 22, iii410-iii410. | 1.2 | 0 |
| 147 | PATH-11. PROSPECTIVE (EPI-)GENETIC CLASSIFICATION OF > 1,000 PEDIATRIC CNS TUMORSâ€”THE MNP 2.0 STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii426-iii426. | 1.2 | 0 |
| 148 | IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation proteinâ€”specific PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2569-2580. | 6.4 | 94 |
| 149 | Mutant IDH Sensitizes Gliomas to Endoplasmic Reticulum Stress and Triggers Apoptosis via miR-183-Mediated Inhibition of Semaphorin 3E. <i>Cancer Research</i> , 2019, 79, 4994-5007. | 0.9 | 28 |
| 150 | MYCN amplification drives an aggressive form of spinal ependymoma. <i>Acta Neuropathologica</i> , 2019, 138, 1075-1089. | 7.7 | 104 |
| 151 | Incidence, mortality and outcome of meningiomas: A population-based study from Germany. <i>Cancer Epidemiology</i> , 2019, 62, 101562. | 1.9 | 90 |
| 152 | Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma. <i>Cancers</i> , 2019, 11, 1072. | 3.7 | 16 |
| 153 | Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. <i>Acta Neuropathologica</i> , 2019, 138, 827-835. | 7.7 | 42 |
| 154 | Microscopic brain invasion in meningiomas previously classified as WHO grade I is not associated with patient outcome. <i>Journal of Neuro-Oncology</i> , 2019, 145, 469-477. | 2.9 | 26 |
| 155 | Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. <i>Acta Neuropathologica Communications</i> , 2019, 7, 163. | 5.2 | 37 |
| 156 | Primary CNS Alveolar Rhabdomyosarcoma: Importance of Epigenetic and Transcriptomic Assays for Accurate Diagnosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 1073-1075. | 1.7 | 6 |
| 157 | Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT. <i>Acta Neuropathologica Communications</i> , 2019, 7, 140. | 5.2 | 26 |
| 158 | Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma. <i>Cancers</i> , 2019, 11, 122. | 3.7 | 25 |
| 159 | Targeted Genomic Profiling of Acral Melanoma. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1068-1077. | 6.3 | 118 |
| 160 | Advances in multidisciplinary therapy for meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i18-i31. | 1.2 | 102 |
| 161 | Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas. <i>Clinical Cancer Research</i> , 2019, 25, 5260-5270. | 7.0 | 23 |
| 162 | Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. <i>Acta Neuropathologica</i> , 2019, 138, 497-504. | 7.7 | 57 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 163 | DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. <i>Neuro-Oncology</i> , 2019, 21, 901-910. | 1.2 | 184 |
| 164 | GENE-08. THE MNP 2.0 STUDY: PROSPECTIVE INTEGRATION OF DNA METHYLATION PROFILING IN CNS TUMOR DIAGNOSTICS. <i>Neuro-Oncology</i> , 2019, 21, ii82-ii82. | 1.2 | 2 |
| 165 | Calcifying fibrous tumor and inflammatory myofibroblastic tumor are epigenetically related: A comparative genome-wide methylation study. <i>Annals of Diagnostic Pathology</i> , 2019, 41, 102-105. | 1.3 | 10 |
| 166 | Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1255-1268. | 3.8 | 45 |
| 167 | Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. <i>Acta Neuropathologica</i> , 2019, 138, 295-308. | 7.7 | 74 |
| 168 | GENE-12. ANAPLASTIC NEUROEPITHELIAL TUMOR WITH CONDENSED NUCLEI (ANTCON): A NOVEL BRAIN TUMOR ENTITY WITH RECURRENT NTRK FUSION. <i>Neuro-Oncology</i> , 2019, 21, ii83-ii83. | 1.2 | 1 |
| 169 | RhoA regulates translation of the Nogo-A decoy SPARC in white matter-invading glioblastomas. <i>Acta Neuropathologica</i> , 2019, 138, 275-293. | 7.7 | 6 |
| 170 | Impact of post-surgical freezing delay on brain tumor metabolomics. <i>Metabolomics</i> , 2019, 15, 78. | 3.0 | 9 |
| 171 | Identification of KIF11 As a Novel Target in Meningioma. <i>Cancers</i> , 2019, 11, 545. | 3.7 | 31 |
| 172 | GENE-06. DISTINCT MOLECULAR SUBGROUPS OF TUMORS OF THE PINEAL REGION CORRELATE WITH CLINICAL PARAMETERS AND GENETIC ALTERATIONS. <i>Neuro-Oncology</i> , 2019, 21, ii81-ii82. | 1.2 | 0 |
| 173 | LGG-13. PAPILLARY GLIONEURONAL TUMOR (PGNT) EXHIBITS A CHARACTERISTIC METHYLATION PROFILE AND MANDATORY FUSIONS INVOLVING PRKCA. <i>Neuro-Oncology</i> , 2019, 21, ii101-ii102. | 1.2 | 0 |
| 174 | Molecular progression of SHH-activated medulloblastomas. <i>Acta Neuropathologica</i> , 2019, 138, 327-330. | 7.7 | 2 |
| 175 | Association Between Tumor Compartment Volumes, the Incidence of Pretreatment Seizures, and Statin-Mediated Protective Effects in Glioblastoma. <i>Neurosurgery</i> , 2019, 85, E722-E729. | 1.1 | 17 |
| 176 | DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1- <i>NFATc2</i> fusion from Ewing sarcoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1273-1281. | 2.5 | 50 |
| 177 | Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. <i>Acta Neuropathologica Communications</i> , 2019, 7, 24. | 5.2 | 101 |
| 178 | Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotype. <i>Clinical Sarcoma Research</i> , 2019, 9, 2. | 2.3 | 48 |
| 179 | Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. <i>Cancer Cell</i> , 2019, 35, 692-704.e12. | 16.8 | 172 |
| 180 | Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. <i>Lancet Oncology</i> , The, 2019, 20, 728-740. | 10.7 | 271 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 181 | Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1. <i>Acta Neuropathologica</i> , 2019, 137, 847-850. | 7.7 | 7 |
| 182 | CIC protein instability contributes to tumorigenesis in glioblastoma. <i>Nature Communications</i> , 2019, 10, 661. | 12.8 | 63 |
| 183 | Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles. <i>Acta Neuropathologica</i> , 2019, 137, 1003-1015. | 7.7 | 9 |
| 184 | Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. <i>Acta Neuropathologica</i> , 2019, 137, 837-846. | 7.7 | 43 |
| 185 | Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas. <i>Acta Neuropathologica Communications</i> , 2019, 7, 201. | 5.2 | 13 |
| 186 | The molecular landscape of ETMR at diagnosis and relapse. <i>Nature</i> , 2019, 576, 274-280. | 27.8 | 94 |
| 187 | Actively personalized vaccination trial for newly diagnosed glioblastoma. <i>Nature</i> , 2019, 565, 240-245. | 27.8 | 637 |
| 188 | Ectopic intracranial retinoblastoma in a 3.5-month-old infant without eye involvement and without evidence of heritability. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27599. | 1.5 | 3 |
| 189 | Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life. <i>Neuro-Oncology</i> , 2019, 21, i32-i43. | 1.2 | 56 |
| 190 | Characterization of the epithelial membrane protein 3 interaction network reveals a potential functional link to mitogenic signal transduction regulation. <i>International Journal of Cancer</i> , 2019, 145, 461-473. | 5.1 | 9 |
| 191 | Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. <i>Acta Neuropathologica</i> , 2019, 137, 521-525. | 7.7 | 51 |
| 192 | Imaging and diagnostic advances for intracranial meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i44-i61. | 1.2 | 100 |
| 193 | Molecular and translational advances in meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i4-i17. | 1.2 | 92 |
| 194 | The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. <i>Clinical Cancer Research</i> , 2019, 25, 1851-1866. | 7.0 | 55 |
| 195 | DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas. <i>Neuro-Oncology</i> , 2019, 21, 214-221. | 1.2 | 31 |
| 196 | N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 95-105. | 1.2 | 100 |
| 197 | Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib. <i>Clinical Cancer Research</i> , 2019, 25, 253-265. | 7.0 | 42 |
| 198 | Identification of New Inhibitors of Mutant Isocitrate Dehydrogenase 2 through Molecular Similarity-based Virtual Screening. <i>Letters in Drug Design and Discovery</i> , 2019, 16, 861-867. | 0.7 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Development and Validation of an Individualized Predictor of Meningioma Recurrence: A Multicenter Retrospective Cohort Study. , 2019, 80, . | | 0 |
| 200 | Abstract A020: Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma. , 2019, , . | | 0 |
| 201 | Abstract B075: Modeling response and resistance to immune checkpoint blockade in syngeneic mouse glioma. , 2019, , . | | 0 |
| 202 | Abstract PR15: The oncometabolite R-2-Hydroxyglutarate suppresses the innate immune microenvironment of IDH1-mutated gliomas via aryl hydrocarbon receptor signaling. , 2019, , . | | 0 |
| 203 | Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup.. Journal of Clinical Oncology, 2019, 37, 2013-2013. | 1.6 | 0 |
| 204 | Efficacy of re-irradiation with carbon ions (RiCi) in patients with recurrent high-grade glioma (rHGG) compared to the standard re-irradiation with photons (RiP): The reference multicenter cohort of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).. Journal of Clinical Oncology, 2019, 37, 2057-2057. | 1.6 | 2 |
| 205 | Abstract 2182: Preclinical in vitro and in vivo combination therapies for mutant IDH1R132 tumors with BAY 1436032. , 2019, , . | | 0 |
| 206 | Abstract 3646: (Epi-)genomic homogeneity in radiation-induced glioblastoma with recurrentPDGFRAamplification and loss ofCDKN2A/Bfollowing primary acute lymphatic leukemia and medulloblastoma. , 2019, , . | | 0 |
| 207 | Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica, 2018, 136, 153-166. | 7.7 | 298 |
| 208 | Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathologica, 2018, 135, 955-963. | 7.7 | 109 |
| 209 | Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma. Molecular Cancer Research, 2018, 16, 767-776. | 3.4 | 25 |
| 210 | The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathologica, 2018, 135, 601-615. | 7.7 | 76 |
| 211 | IDH1 mutant glioma initiating cells are predisposed to apoptosis under endoplasmic reticulum (ER) stress. Neuro-Oncology, 2018, 20, i13-i13. | 1.2 | 1 |
| 212 | Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis. Journal of Neuropathology and Experimental Neurology, 2018, 77, 422-425. | 1.7 | 57 |
| 213 | Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylationâ€”the NCT Neuro Master Match (N2M2) pilot study. Neuro-Oncology, 2018, 20, 826-837. | 1.2 | 32 |
| 214 | Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 388-393. | 2.2 | 15 |
| 215 | Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. Acta Neuropathologica Communications, 2018, 6, 21. | 5.2 | 28 |
| 216 | DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathologica, 2018, 136, 255-271. | 7.7 | 59 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 217 | DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474. | 27.8 | 1,872 |
| 218 | A PRDX1΁– heterodimer amplifies MET–driven invasion of <i>IDH</i>–wildtype and <i>IDH</i>–mutant gliomas. <i>International Journal of Cancer</i> , 2018, 143, 1176-1187. | 5.1 | 14 |
| 219 | Extra-small dual-lumen micro-balloon catheters can improve endovascular embolization: an experimental in vivo and in vitro study. <i>Journal of NeuroInterventional Surgery</i> , 2018, 10, 1092-1096. | 3.3 | 17 |
| 220 | Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. <i>Acta Neuropathologica</i> , 2018, 136, 273-291. | 7.7 | 190 |
| 221 | Molecular characterization of medulloblastomas with extensive nodularity (MBEN). <i>Acta Neuropathologica</i> , 2018, 136, 303-313. | 7.7 | 20 |
| 222 | Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma. <i>Clinical Cancer Research</i> , 2018, 24, 2951-2962. | 7.0 | 25 |
| 223 | Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information. <i>Modern Pathology</i> , 2018, 31, 1246-1256. | 5.5 | 76 |
| 224 | Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing. <i>Seminars in Neurology</i> , 2018, 38, 019-023. | 1.4 | 30 |
| 225 | Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. <i>Journal of Neurosurgery</i> , 2018, 128, 1102-1114. | 1.6 | 26 |
| 226 | Evaluation of a novel liquid embolic agent (precipitating hydrophobic injectable liquid (PHIL)) in an animal endovascular embolization model. <i>Journal of NeuroInterventional Surgery</i> , 2018, 10, 268-274. | 3.3 | 29 |
| 227 | Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 848-857. | 1.2 | 170 |
| 228 | Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. <i>Brain Pathology</i> , 2018, 28, 656-662. | 4.1 | 89 |
| 229 | Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. <i>Neuro-Oncology</i> , 2018, 20, 367-379. | 1.2 | 79 |
| 230 | Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs. <i>Modern Pathology</i> , 2018, 31, 160-168. | 5.5 | 4 |
| 231 | Proteomics in Pathology. <i>Proteomics</i> , 2018, 18, 1700361. | 2.2 | 18 |
| 232 | TBIO-10. PEDIATRIC TARGETED THERAPY 2.0: DEVELOPMENT OF PERSONALIZED PEDIATRIC ONCOLOGY. <i>Neuro-Oncology</i> , 2018, 20, i182-i182. | 1.2 | 0 |
| 233 | Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children–s Oncology Group Randomized ACNS0332 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3388-3395. | 1.6 | 58 |
| 234 | CSIG-27. DIFFERENTIAL ELEVATION OF TERT ACTIVITY AND SENSITIVITY TO TEMOZOLOMIDE BY TYPE OF TERT MUTATION IN MGMT PROMOTER-METHYLATED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi48-vi49. | 1.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 235 | LGG-11. REGULATION OF ONCOGENE-INDUCED SENESENCE IN PILOCYTIC ASTROCYTOMA. <i>Neuro-Oncology</i> , 2018, 20, i106-i106. | 1.2 | 0 |
| 236 | TBIO-07. ASSESSING THE UTILITY OF DNA METHYLATION PROFILING IN BRAIN TUMOR DIAGNOSTICSâ€”THE PROSPECTIVE MNP2.0 STUDY. <i>Neuro-Oncology</i> , 2018, 20, i181-i181. | 1.2 | 0 |
| 237 | cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” <i>Acta Neuropathologica</i> , 2018, 136, 805-810. | 7.7 | 599 |
| 238 | Frame-based stereotactic biopsies using an intraoperative MR-scanner are as safe and effective as conventional stereotactic procedures. <i>PLoS ONE</i> , 2018, 13, e0205772. | 2.5 | 11 |
| 239 | Nonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1472-1480. | 0.8 | 5 |
| 240 | Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. <i>Acta Neuropathologica</i> , 2018, 136, 975-978. | 7.7 | 11 |
| 241 | Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. <i>Acta Neuropathologica</i> , 2018, 136, 793-803. | 7.7 | 195 |
| 242 | Post-operative cardiovascular complications and time to recurrence in meningioma patients treated with versus without pre-operative embolization: a retrospective cohort study of 741 patients. <i>Journal of Neuro-Oncology</i> , 2018, 140, 659-667. | 2.9 | 10 |
| 243 | Diagnostic accuracy of DW MR imaging in the differentiation of chordomas and chondrosarcomas of the skull base: A 3.0-T MRI study of 105 cases. <i>European Journal of Radiology</i> , 2018, 105, 119-124. | 2.6 | 24 |
| 244 | Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8981-9003. | 6.4 | 23 |
| 245 | Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. <i>Acta Neuropathologica</i> , 2018, 136, 239-253. | 7.7 | 118 |
| 246 | FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. <i>Acta Neuropathologica</i> , 2018, 136, 293-302. | 7.7 | 56 |
| 247 | MBCL-21. EARLY CHILDHOOD MEDULLOBLASTOMA: SUBGROUP-SPECIFIC SURVIVAL IN PATIENTS TREATED WITH SYSTEMIC CHEMOTHERAPY AND INTRAVENTRICULAR MTX TO AVOID CRANIOSPINAL RADIOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, i121-i121. | 1.2 | 0 |
| 248 | Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. <i>Acta Neuropathologica</i> , 2018, 136, 181-210. | 7.7 | 308 |
| 249 | EGFL7 enhances surface expression of integrin $\alpha_5\beta_1$ to promote angiogenesis in malignant brain tumors. <i>EMBO Molecular Medicine</i> , 2018, 10, . | 6.9 | 33 |
| 250 | DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. <i>Neuro-Oncology</i> , 2018, 20, 1616-1624. | 1.2 | 65 |
| 251 | Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 2132-2145. | 3.8 | 41 |
| 252 | Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. <i>Nature Medicine</i> , 2018, 24, 1192-1203. | 30.7 | 359 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 253 | BRAF V600E Mutations in Nevi and Melanocytic Tumors of Uncertain Malignant Potential. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2489-2491. | 0.7 | 5 |
| 254 | Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making – A Selected Case Series. <i>Klinische Padiatrie</i> , 2018, 230, 305-313. | 0.6 | 8 |
| 255 | Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1573-1584. | 6.4 | 18 |
| 256 | Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma. <i>Neuro-Oncology</i> , 2018, 20, 1517-1524. | 1.2 | 36 |
| 257 | Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. <i>Acta Neuropathologica</i> , 2018, 136, 327-337. | 7.7 | 104 |
| 258 | Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling. <i>Clinical Cancer Research</i> , 2018, 24, 4494-4504. | 7.0 | 28 |
| 259 | LGG-20. MOLECULARLY-DEFINED DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR (DLGNT) COMPRISES TWO SUBGROUPS WITH DISTINCT CLINICAL AND GENETIC FEATURES. <i>Neuro-Oncology</i> , 2018, 20, i108-i108. | 1.2 | 0 |
| 260 | Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 1004. | 2.8 | 16 |
| 261 | GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2000-2000. | 1.6 | 17 |
| 262 | A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).. <i>Journal of Clinical Oncology</i> , 2018, 36, 2001-2001. | 1.6 | 21 |
| 263 | VXM01 phase I study in patients with progressive glioblastoma: Final results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2017-2017. | 1.6 | 87 |
| 264 | Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2013-2013. | 1.6 | 0 |
| 265 | Methylation among members of the PI3K/AKT/mTOR pathway in melanoma brain and extracerebral metastases.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21515-e21515. | 1.6 | 0 |
| 266 | Towards a molecular algorithm predicting glioma treatment response and resistance: A biomarker analysis and path to real time profiling in N2M2.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12090-12090. | 1.6 | 0 |
| 267 | Abstract 1906: PFKFB4, much more than just a glycolytic gene. , 2018, , . | | 0 |
| 268 | Abstract IA11: Pediatric precision oncology programs in Germany and Europe. , 2018, , . | | 0 |
| 269 | IMMU-54. THE ONCOMETABOLITE R-2-HYDROXYGLUTARATE SUPPRESSES THE INNATE IMMUNE MICROENVIRONMENT OF IDH1-MUTATED GLIOMAS VIA ARYL HYDROCARBON RECEPTOR SIGNALING. <i>Neuro-Oncology</i> , 2018, 20, vi133-vi133. | 1.2 | 0 |
| 270 | Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. <i>Acta Neuropathologica</i> , 2017, 133, 629-644. | 7.7 | 146 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 271 | H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. <i>Acta Neuropathologica</i> , 2017, 134, 507-516. | 7.7 | 144 |
| 272 | Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. <i>Acta Neuropathologica</i> , 2017, 134, 155-158. | 7.7 | 26 |
| 273 | Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. <i>Acta Neuropathologica Communications</i> , 2017, 5, 39. | 5.2 | 110 |
| 274 | Diagnostic challenges in meningioma. <i>Neuro-Oncology</i> , 2017, 19, 1588-1598. | 1.2 | 106 |
| 275 | Tweety-Homolog 1 Drives Brain Colonization of Gliomas. <i>Journal of Neuroscience</i> , 2017, 37, 6837-6850. | 3.6 | 129 |
| 276 | Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens. <i>Acta Neuropathologica</i> , 2017, 134, 297-316. | 7.7 | 23 |
| 277 | DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2017, 18, 682-694. | 10.7 | 586 |
| 278 | Copy number variation analysis and methylome profiling of a GNAQ-mutant primary meningeal melanocytic tumor and its liver metastasis. <i>Experimental and Molecular Pathology</i> , 2017, 102, 25-31. | 2.1 | 15 |
| 279 | Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. <i>Acta Neuropathologica</i> , 2017, 133, 325-327. | 7.7 | 12 |
| 280 | Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. <i>Acta Neuropathologica</i> , 2017, 133, 1-3. | 7.7 | 120 |
| 281 | Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. <i>Molecular Therapy</i> , 2017, 25, 2620-2634. | 8.2 | 199 |
| 282 | DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma. <i>Acta Neuropathologica</i> , 2017, 134, 965-967. | 7.7 | 38 |
| 283 | Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 6379-6387. | 3.0 | 10 |
| 284 | Report of a Novel Case of Anaplastic Olfactory Groove Meningioma and Its Methylation Subtype. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 997-999. | 1.7 | 0 |
| 285 | Loss of Mpdz impairs ependymal cell integrity leading to perinatal-onset hydrocephalus in mice. <i>EMBO Molecular Medicine</i> , 2017, 9, 890-905. | 6.9 | 54 |
| 286 | Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 6846-6855. | 7.0 | 151 |
| 287 | The whole-genome landscape of medulloblastoma subtypes. <i>Nature</i> , 2017, 547, 311-317. | 27.8 | 787 |
| 288 | Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. <i>Nature Communications</i> , 2017, 8, 186. | 12.8 | 76 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 289 | GENE-07. MOLECULAR NEUROPATHOLOGY 2.0 - INCREASING DIAGNOSTIC ACCURACY IN PEDIATRIC NEUROONCOLOGY. Neuro-Oncology, 2017, 19, iv19-iv19. | 1.2 | 0 |
| 290 | Grading of diffuse astrocytic gliomas: Broders, Kernohan, ZÃ¼lch, the WHOâ€ and Shakespeare. Acta Neuropathologica, 2017, 134, 517-520. | 7.7 | 15 |
| 291 | Lomustine and Bevacizumab in Progressive Glioblastoma. New England Journal of Medicine, 2017, 377, 1954-1963. | 27.0 | 670 |
| 292 | Molecular Transition of an Adult Low-Grade Brain Tumor to an Atypical Teratoid/Rhabdoid Tumor Over a Time-Course of 14 Years. Journal of Neuropathology and Experimental Neurology, 2017, 76, 655-664. | 1.7 | 13 |
| 293 | Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363. Journal of the National Cancer Institute, 2017, 109, 1-4. | 6.3 | 51 |
| 294 | Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases. Clinical Sarcoma Research, 2017, 7, 9. | 2.3 | 51 |
| 295 | K27M-mutant histone-3 as a novel target for glioma immunotherapy. Oncolmunology, 2017, 6, e1328340. | 4.6 | 74 |
| 296 | cIMPACTâ€NOW (the consortium to inform molecular and practical approaches to CNS tumor) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 46 27, 851-852. | 4.1 | 63 |
| 297 | The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathologica, 2017, 133, 5-12. | 7.7 | 271 |
| 298 | MNGI-02. PREOPERATIVE EMBOLIZATION OF MENINGIOMA: INFERIOR NEUROLOGICAL OUTCOME, INCREASED RISK OF CARDIOVASCULAR COMPLICATIONS AND SHORTER TIME TO RECURRENCE?. Neuro-Oncology, 2017, 19, vi132-vi132. | 1.2 | 0 |
| 299 | NIMG-51. RADIOLOGIC PHENOTYPES ARE TREATMENT SPECIFIC AND ASSOCIATED WITH SURVIVAL - EXPLORATORY ANALYSIS OF EORTC 26101. Neuro-Oncology, 2017, 19, vi153-vi153. | 1.2 | 0 |
| 300 | PATH-24. MOLECULAR SUBGROUPS OF ADULT EPENDYMAL TUMORS: AN ANALYSIS OF THE GERMAN GLIOMA NETWORK. Neuro-Oncology, 2017, 19, vi175-vi176. | 1.2 | 0 |
| 301 | PDTM-47. CHARACTERIZATION OF THE SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE IN PILOCYTIC ASTROCYTOMA AND ITS ROLE IN ONCOGENE-INDUCED SENESCENCE. Neuro-Oncology, 2017, 19, vi200-vi200. | 1.2 | 0 |
| 302 | Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. International Journal of Molecular Sciences, 2017, 18, 995. | 4.1 | 32 |
| 303 | PDCT-05. MOLECULAR DIAGNOSTICS REVEAL 60% HIGHER SURVIVAL FOR MOLECULARLY-VERIFIED VERSUS HISTOPATHOLOGICALLY-DIAGNOSED PEDIATRIC SUPRATENTORIAL CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS AND PINEOBLASTOMAS; Aâ€REPORT FROM THE CHILDRENâ€™S ONCOLOGY GROUP ACNS0332 TRIAL. Neuro-Oncology, 2017, 19, vi184-vi185. | 1.2 | 2 |
| 304 | LGG-04. CHARACTERIZATION OF ONCOGENE-INDUCED SENESCENCE AND THE ROLE OF THE SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE IN PILOCYTIC ASTROCYTOMA. Neuro-Oncology, 2017, 19, iv33-iv33. | 1.2 | 0 |
| 305 | TRTH-09. PTT2.0: DEVELOPING PERSONALIZED PEDIATRIC ONCOLOGY. Neuro-Oncology, 2017, 19, iv53-iv53. | 1.2 | 0 |
| 306 | ACTR-05. THE RANDOMIZED PHASE II ARTE TRIAL: BEVACIZUMAB PLUS HYPOFRACTIONATED RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2017, 19, vi2-vi2. | 1.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 307 | The INFORM personalized medicine study for high-risk pediatric cancer patients.. Journal of Clinical Oncology, 2017, 35, 10509-10509. | 1.6 | 1 |
| 308 | VXM01 phase I study in patients with resectable progression of a glioblastoma.. Journal of Clinical Oncology, 2017, 35, 2061-2061. | 1.6 | 4 |
| 309 | mIDH-associated DNA hypermethylation in acute myeloid leukemia reflects differentiation blockage rather than inhibition of TET-mediated demethylation. Cell Stress, 2017, 1, 55-67. | 3.2 | 3 |
| 310 | Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. Oncotarget, 2017, 8, 11460-11479. | 1.8 | 43 |
| 311 | Clinical and molecular features associated with long-term survival of elderly patients with glioblastoma.. Journal of Clinical Oncology, 2017, 35, 2013-2013. | 1.6 | 0 |
| 312 | LG-27DKFZ-BT66 - A NOVEL PILOCYTIC ASTROCYTOMA MODEL FOR PRECLINICAL DRUG TESTING. Neuro-Oncology, 2016, 18, iii84.3-iii84. | 1.2 | 0 |
| 313 | TB-11 MOLECULAR NEUROPATHOLOGY 2.0 - INCREASING DIAGNOSTIC ACCURACY IN PEDIATRIC NEUROONCOLOGY. Neuro-Oncology, 2016, 18, iii170.4-iii170. | 1.2 | 0 |
| 314 | TB-14 THE INFORM PERSONALIZED MEDICINE STUDY - NEW MOLECULAR INSIGHTS INTO RELAPSED PEDIATRIC BRAIN TUMORS. Neuro-Oncology, 2016, 18, iii171.1-iii171. | 1.2 | 0 |
| 315 | Tryptophanâ€2,3â€dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptorâ€4. Journal of Neurochemistry, 2016, 136, 1142-1154. | 3.9 | 48 |
| 316 | Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. Brain Pathology, 2016, 26, 506-516. | 4.1 | 14 |
| 317 | <i>LOC283731</i> promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients. International Journal of Cancer, 2016, 139, 424-432. | 5.1 | 18 |
| 318 | Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology, 2016, 18, now133. | 1.2 | 130 |
| 319 | Differential nuclear <sc>ATRX</sc> expression in sarcomas. Histopathology, 2016, 68, 738-745. | 2.9 | 19 |
| 320 | Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. Brain Pathology, 2016, 26, 199-205. | 4.1 | 39 |
| 321 | RINT1 functions as a multitasking protein at the crossroads between genomic stability, ER homeostasis, and autophagy. Autophagy, 2016, 12, 1413-1415. | 9.1 | 5 |
| 322 | Somatic mutations of <i>DICER1</i> and <i>KMT2D</i> are frequent in intraocular medulloepitheliomas. Genes Chromosomes and Cancer, 2016, 55, 418-427. | 2.8 | 34 |
| 323 | Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone. BMC Medicine, 2016, 14, 170. | 5.5 | 31 |
| 324 | <i>IDH2</i> Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. Cancer Research, 2016, 76, 7118-7129. | 0.9 | 99 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 325 | Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 370-377. | 2.8 | 25 |
| 326 | Radiotherapy plus concomitant temozolomide in primary gliosarcoma. <i>Journal of Neuro-Oncology</i> , 2016, 128, 341-348. | 2.9 | 26 |
| 327 | The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. <i>Acta Neuropathologica</i> , 2016, 131, 803-820. | 7.7 | 12,144 |
| 328 | EANO guidelines for the diagnosis and treatment of meningiomas. <i>Lancet Oncology</i> , The, 2016, 17, e383-e391. | 10.7 | 627 |
| 329 | Identification of a novel selective inhibitor of mutant isocitrate dehydrogenase 1 at allosteric site by docking-based virtual screening. <i>RSC Advances</i> , 2016, 6, 96735-96742. | 3.6 | 13 |
| 330 | Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology</i> , The, 2016, 17, 1521-1532. | 10.7 | 396 |
| 331 | HG-68COMBINED ALTERATIONS IN MAPK PATHWAY GENES, CDKN2A/B AND ATRX CHARACTERIZE ANAPLASTIC PILOCYTIC ASTROCYTOMA. <i>Neuro-Oncology</i> , 2016, 18, iii63.2-iii63. | 1.2 | 0 |
| 332 | Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. <i>European Journal of Cancer</i> , 2016, 65, 91-101. | 2.8 | 262 |
| 333 | Evidence of H3 K27M mutations in posterior fossa ependymomas. <i>Acta Neuropathologica</i> , 2016, 132, 635-637. | 7.7 | 73 |
| 334 | Radiogenomics of Glioblastoma: Machine Learning–based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. <i>Radiology</i> , 2016, 281, 907-918. | 7.3 | 236 |
| 335 | Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients. <i>BMC Cancer</i> , 2016, 16, 81. | 2.6 | 51 |
| 336 | Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. <i>Acta Neuropathologica Communications</i> , 2016, 4, 20. | 5.2 | 136 |
| 337 | Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis. <i>Journal of Neuro-Oncology</i> , 2016, 129, 319-328. | 2.9 | 25 |
| 338 | Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. <i>Acta Neuropathologica</i> , 2016, 131, 903-910. | 7.7 | 203 |
| 339 | Methylation-based classification of benign and malignant peripheral nerve sheath tumors. <i>Acta Neuropathologica</i> , 2016, 131, 877-887. | 7.7 | 151 |
| 340 | Prognostic factors and long-term survival in surgically treated brain metastases from non-small cell lung cancer. <i>Clinical Neurology and Neurosurgery</i> , 2016, 142, 72-80. | 1.4 | 26 |
| 341 | Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. <i>Neuro-Oncology</i> , 2016, 18, 790-796. | 1.2 | 67 |
| 342 | Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. <i>Cancer Cell</i> , 2016, 29, 379-393. | 16.8 | 438 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 343 | New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072. | 28.9 | 702 |
| 344 | TERT Promoter Mutations and Risk of Recurrence in Meningioma. Journal of the National Cancer Institute, 2016, 108, djv377. | 6.3 | 283 |
| 345 | Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropathologica, 2016, 131, 309-319. | 7.7 | 74 |
| 346 | Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathologica, 2016, 131, 137-146. | 7.7 | 162 |
| 347 | Abstract 2645: BAY 1436032: A highly selective, potent and orally available inhibitor of mutant forms of IDH1. , 2016, , . | | 1 |
| 348 | Abstract 2654: GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma. , 2016, , . | | 1 |
| 349 | Pan-Mutant-IDH1 Inhibitor Bay-1436032 Is Highly Effective Against Human IDH1 Mutant Acute Myeloid Leukemia In Vivo. Blood, 2016, 128, 745-745. | 1.4 | 7 |
| 350 | EGFR gene amplification and variant III (EGFRvIII) mutation in primary and recurrent glioblastoma.. Journal of Clinical Oncology, 2016, 34, 2042-2042. | 1.6 | 3 |
| 351 | A mutation-specific peptide vaccine targeting <i>IDH1R132H</i> in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).. Journal of Clinical Oncology, 2016, 34, TPS2082-TPS2082. | 1.6 | 6 |
| 352 | Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (NÄ²MÄ²).. Journal of Clinical Oncology, 2016, 34, TPS2084-TPS2084. | 1.6 | 4 |
| 353 | MYCN and HDAC5 transcriptionally repress <i>CD9</i> to trigger invasion and metastasis in neuroblastoma. Oncotarget, 2016, 7, 66344-66359. | 1.8 | 30 |
| 354 | Prognostic relevance of miRNA-155 methylation in anaplastic glioma. Oncotarget, 2016, 7, 82028-82045. | 1.8 | 21 |
| 355 | Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade. Oncotarget, 2016, 7, 14551-14568. | 1.8 | 36 |
| 356 | Epidermal <i>Nbn</i> deletion causes premature hair loss and a phenotype resembling psoriasiform dermatitis. Oncotarget, 2016, 7, 23006-23018. | 1.8 | 5 |
| 357 | Abstract 11: Advancing methylation profiling in neuropathology: Diagnosis and clinical management. , 2016, , . | | 0 |
| 358 | Abstract 4277: Development and validation of a novel IDH1-mutant astrocyte cell line as a model for high-grade gliomas. , 2016, , . | | 0 |
| 359 | Abstract 138: Solid papillary carcinoma with reverse polarization are driven by IDH2 and PI3K pathway mutations. , 2016, , . | | 1 |
| 360 | ANGI-08RADIOGENOMIC rCBV-IMAGING VISUALIZES THE DISTINCT ANGIOGENESIS TRANSCRIPTOME SIGNATURES OF IDH MUTANT AND WILD-TYPE GLIOMAS. Neuro-Oncology, 2015, 17, v42.3-v42. | 1.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 361 | Validation of a Manual Protocol for BRAF V600E Mutation-specific Immunohistochemistry. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 382-388. | 1.2 | 7 |
| 362 | IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Scientific Reports, 2015, 5, 16238. | 3.3 | 259 |
| 363 | SURG-16PROGNOSTIC VALUE OF THE EXTENT OF RESECTION AND IDH1 MUTATION STATUS IN WHO GRADE II ASTROCYTOMAS. Neuro-Oncology, 2015, 17, v217.4-v217. | 1.2 | 0 |
| 364 | IMPS-14PROGNOSTIC ROLE OF REGULATORY T-CELLS IN PRIMARY AND RECURRENT MENINGIOMA. Neuro-Oncology, 2015, 17, v116.1-v116. | 1.2 | 2 |
| 365 | Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. Neuropathology, 2015, 35, 538-544. | 1.2 | 38 |
| 366 | Retinoid resistance and multifaceted impairment of retinoic acid synthesis in glioblastoma. Glia, 2015, 63, 1850-1859. | 4.9 | 13 |
| 367 | Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients. Oncotarget, 2015, 6, 13579-13590. | 1.8 | 21 |
| 368 | Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell, 2015, 27, 728-743. | 16.8 | 933 |
| 369 | Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis. Journal of Neuro-Oncology, 2015, 124, 265-273. | 2.9 | 16 |
| 370 | Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. Acta Neuropathologica, 2015, 130, 419-434. | 7.7 | 74 |
| 371 | IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathologica, 2015, 129, 867-873. | 7.7 | 272 |
| 372 | Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. Neuropathology and Applied Neurobiology, 2015, 41, 694-720. | 3.2 | 83 |
| 373 | Melanotic Tumors of the Nervous System are Characterized by Distinct Mutational, Chromosomal and Epigenomic Profiles. Brain Pathology, 2015, 25, 202-208. | 4.1 | 66 |
| 374 | <scp><i>BRAF V</i></scp><i>600</i><scp><i>E</i></scp> analysis for the differentiation of papillary craniopharyngiomas and <scp>R</scp>athke's cleft cysts. Neuropathology and Applied Neurobiology, 2015, 41, 733-742. | 3.2 | 50 |
| 375 | Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas. Modern Pathology, 2015, 28, 187-200. | 5.5 | 134 |
| 376 | Farewell to oligoastrocytoma: response to letters. Acta Neuropathologica, 2015, 129, 155-155. | 7.7 | 7 |
| 377 | Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathologica, 2015, 129, 669-678. | 7.7 | 277 |
| 378 | Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathologica, 2015, 130, 407-417. | 7.7 | 237 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 379 | Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2015, 372, 2481-2498. | 27.0 | 2,582 |
| 380 | Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2015, 3, 22. | 5.2 | 66 |
| 381 | Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. <i>Acta Neuropathologica</i> , 2015, 129, 679-693. | 7.7 | 254 |
| 382 | Glioblastoma: pathology, molecular mechanisms and markers. <i>Acta Neuropathologica</i> , 2015, 129, 829-848. | 7.7 | 503 |
| 383 | Brain tumour cells interconnect to a functional and resistant network. <i>Nature</i> , 2015, 528, 93-98. | 27.8 | 787 |
| 384 | ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. <i>Acta Neuropathologica</i> , 2015, 129, 133-146. | 7.7 | 378 |
| 385 | BRAF ^{V600E} -mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1596-1602. | 0.9 | 94 |
| 386 | Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. <i>Glia</i> , 2015, 63, 78-90. | 4.9 | 51 |
| 387 | Proximity ligation assay evaluates IDH1R132H presentation in gliomas. <i>Journal of Clinical Investigation</i> , 2015, 125, 593-606. | 8.2 | 35 |
| 388 | Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2001-2001. | 1.6 | 9 |
| 389 | Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in patients with a high risk low-grade glioma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2006-2006. | 1.6 | 7 |
| 390 | Molecular classification of diffuse cerebral gliomas using genome- and transcriptome-wide profiling.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2007-2007. | 1.6 | 1 |
| 391 | Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. <i>Oncotarget</i> , 2015, 6, 31050-31068. | 1.8 | 52 |
| 392 | Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13046-e13046. | 1.6 | 0 |
| 393 | Abstract LB-114: The INFORM personalized medicine study for high-risk pediatric cancer patients. , 2015, , . | | 0 |
| 394 | Survival According to BRAF-V600 Tumor Mutations " An Analysis of 437 Patients with Primary Melanoma. <i>PLoS ONE</i> , 2014, 9, e86194. | 2.5 | 42 |
| 395 | BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. <i>Modern Pathology</i> , 2014, 27, 1028-1034. | 5.5 | 96 |
| 396 | Detection of<i>BRAF</i>p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 71-75. | 2.5 | 57 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 397 | Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. <i>Neuro-Oncology</i> , 2014, 16, 1630-1638. | 1.2 | 77 |
| 398 | Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. <i>Acta Neuropathologica</i> , 2014, 128, 879-891. | 7.7 | 54 |
| 399 | Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. <i>International Journal of Cancer</i> , 2014, 134, 2437-2447. | 5.1 | 100 |
| 400 | MAP kinase activity supported by BRAF V600E mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases. <i>Archives of Dermatological Research</i> , 2014, 306, 873-884. | 1.9 | 11 |
| 401 | mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 409-414. | 7.1 | 152 |
| 402 | Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms. <i>Acta Neuropathologica</i> , 2014, 127, 565-572. | 7.7 | 41 |
| 403 | High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. <i>Lung Cancer</i> , 2014, 83, 83-89. | 2.0 | 63 |
| 404 | Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. <i>International Journal of Cancer</i> , 2014, 135, 1822-1831. | 5.1 | 117 |
| 405 | Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothed Inhibition. <i>Cancer Cell</i> , 2014, 25, 393-405. | 16.8 | 627 |
| 406 | Diagnostic Value of Immunohistochemistry for the Detection of the <i>BRAF</i> ^{V600E} Mutation in Papillary Thyroid Carcinoma: Comparative Analysis with Three DNA-Based Assays. <i>Thyroid</i> , 2014, 24, 858-866. | 4.5 | 57 |
| 407 | Nuclear relocation of <i>STAT</i> 6 reliably predicts <i>NAB2</i> – <i>STAT6</i> fusion for the diagnosis of solitary fibrous tumour. <i>Histopathology</i> , 2014, 65, 613-622. | 2.9 | 101 |
| 408 | Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. <i>Neuro-Oncology</i> , 2014, 16, 914-923. | 1.2 | 69 |
| 409 | <i>BRAF</i> –Mutated Pleomorphic Xanthoastrocytoma is Associated with Temporal Location, Reticulin Fiber Deposition and <i>CD</i> 34 Expression. <i>Brain Pathology</i> , 2014, 24, 221-229. | 4.1 | 72 |
| 410 | Aberrant self-renewal and quiescence contribute to the aggressiveness of glioblastoma. <i>Journal of Pathology</i> , 2014, 234, 23-33. | 4.5 | 53 |
| 411 | <i>GRHL1</i> Acts as Tumor Suppressor in Neuroblastoma and Is Negatively Regulated by MYCN and HDAC3. <i>Cancer Research</i> , 2014, 74, 2604-2616. | 0.9 | 54 |
| 412 | Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. <i>Acta Neuropathologica</i> , 2014, 128, 279-289. | 7.7 | 191 |
| 413 | Amplification and overexpression of <i>CMET</i> is a common event in brain metastases of non-small cell lung cancer. <i>Histopathology</i> , 2014, 65, 684-692. | 2.9 | 25 |
| 414 | Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E. <i>Modern Pathology</i> , 2014, 27, 135-144. | 5.5 | 49 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 415 | In situ proximity ligation assay to evaluate presentation of a mutated CD4 epitope in human glioma tissue. Journal of Neuroimmunology, 2014, 275, 35. | 2.3 | 0 |
| 416 | Mutant IDH1R132H bears a mutation-specific CD4 T cell epitope suitable for vaccination of human CNS tumors. Journal of Neuroimmunology, 2014, 275, 39. | 2.3 | 0 |
| 417 | A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma. Clinical Cancer Research, 2014, 20, 6304-6313. | 7.0 | 111 |
| 418 | International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading. Brain Pathology, 2014, 24, 429-435. | 4.1 | 499 |
| 419 | Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants. Acta Neuropathologica, 2014, 128, 449-452. | 7.7 | 36 |
| 420 | TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. Journal of Experimental and Clinical Cancer Research, 2014, 33, 33. | 8.6 | 74 |
| 421 | D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. Acta Neuropathologica Communications, 2014, 2, 19. | 5.2 | 72 |
| 422 | Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathologica, 2014, 128, 561-571. | 7.7 | 176 |
| 423 | Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathologica, 2014, 128, 551-559. | 7.7 | 268 |
| 424 | Enhancer hijacking activates GF11 family oncogenes in medulloblastoma. Nature, 2014, 511, 428-434. | 27.8 | 520 |
| 425 | A vaccine targeting mutant IDH1 induces antitumour immunity. Nature, 2014, 512, 324-327. | 27.8 | 613 |
| 426 | MGMT testing—the challenges for biomarker-based glioma treatment. Nature Reviews Neurology, 2014, 10, 372-385. | 10.1 | 454 |
| 427 | Final results of APG101_CD_002: APG101 plus reirradiation versus reirradiation in the treatment of patients with progressive glioblastoma.. Journal of Clinical Oncology, 2014, 32, 2006-2006. | 1.6 | 2 |
| 428 | Do host factors determine long-term survival in glioblastoma? A genome/transcriptome profiling study by the German Glioma Network.. Journal of Clinical Oncology, 2014, 32, 2014-2014. | 1.6 | 11 |
| 429 | Determining the glioma CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide methylation data in the biomarker cohort of the NOA-04 trial.. Journal of Clinical Oncology, 2014, 32, 2017-2017. | 1.6 | 3 |
| 430 | Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget, 2014, 5, 1038-1051. | 1.8 | 248 |
| 431 | Abstract 3093: Unravelling the biology of aggressive and therapy-resistant embryonal tumors with multilayered rosettes (ETMR). , 2014, , . | | 0 |
| 432 | Abstract 1889: Next-generation neuropathology - Improving diagnostic accuracy for brain tumors using DNA methylation array-based molecular profiling. , 2014, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 433 | Abstract 3094: Epigenetic classification of ependymal brain tumors across age groups. , 2014, , . | | 0 |
| 434 | Interlaboratory comparison of IDH mutation detection. Journal of Neuro-Oncology, 2013, 112, 173-178. | 2.9 | 59 |
| 435 | Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genetics, 2013, 45, 927-932. | 21.4 | 674 |
| 436 | Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and \pm -KG. Acta Neuropathologica Communications, 2013, 1, 18. | 5.2 | 54 |
| 437 | ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathologica, 2013, 126, 443-451. | 7.7 | 304 |
| 438 | Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathologica, 2013, 125, 891-900. | 7.7 | 177 |
| 439 | Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathologica, 2013, 125, 651-658. | 7.7 | 324 |
| 440 | Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathologica, 2013, 125, 351-358. | 7.7 | 208 |
| 441 | BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. International Journal of Cancer, 2013, 133, 1624-1630. | 5.1 | 93 |
| 442 | Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathologica, 2013, 126, 907-915. | 7.7 | 254 |
| 443 | AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathologica, 2013, 126, 757-762. | 7.7 | 88 |
| 444 | Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. Cancer Cell, 2013, 24, 660-672. | 16.8 | 633 |
| 445 | The Endogenous Tryptophan Metabolite and NAD+ Precursor Quinolinic Acid Confers Resistance of Gliomas to Oxidative Stress. Cancer Research, 2013, 73, 3225-3234. | 0.9 | 126 |
| 446 | Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. Journal of Neuroimmunology, 2013, 265, 106-116. | 2.3 | 81 |
| 447 | Prognostic or predictive value of <i>MGMT</i> promoter methylation in gliomas depends on <i>IDH1</i> mutation. Neurology, 2013, 81, 1515-1522. | 1.1 | 211 |
| 448 | Clonal BRAF Mutations in Melanocytic Nevi and Initiating Role of BRAF in Melanocytic Neoplasia. Journal of the National Cancer Institute, 2013, 105, 917-919. | 6.3 | 92 |
| 449 | Highly prevalent <i>TERT</i> promoter mutations in bladder cancer and glioblastoma. Cell Cycle, 2013, 12, 1637-1638. | 2.6 | 123 |
| 450 | Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Human Pathology, 2013, 44, 329-335. | 2.0 | 77 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 451 | TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 126, 917-929. | 7.7 | 146 |
| 452 | ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 80, 278-283. | 2.0 | 59 |
| 453 | Detection of BRAF p.V600E Mutations in Melanomas. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 94-100. | 2.8 | 144 |
| 454 | Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs. <i>Translational Oncology</i> , 2013, 6, 685-IN18. | 3.7 | 25 |
| 455 | Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2013, 18, 1416-1425. | 4.9 | 62 |
| 456 | Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. <i>Neuro-Oncology</i> , 2013, 15, 1405-1412. | 1.2 | 53 |
| 457 | Functional MHC Class II Is Upregulated in Neurofibromin-Deficient Schwann Cells. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1372-1375. | 0.7 | 6 |
| 458 | No Evidence for BRAF-V600E Mutations in Gastroesophageal Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 426-430. | 1.2 | 12 |
| 459 | BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1592-1602. | 3.7 | 125 |
| 460 | Expression of BRAF V600E Mutant Protein in Epithelial Ovarian Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 159-164. | 1.2 | 27 |
| 461 | Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations. <i>Clinical Cancer Research</i> , 2013, 19, 5146-5157. | 7.0 | 157 |
| 462 | Targeting the BRAF V600E Mutation in Multiple Myeloma. <i>Cancer Discovery</i> , 2013, 3, 862-869. | 9.4 | 202 |
| 463 | Protein kinase C δ as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 14735-14740. | 7.1 | 43 |
| 464 | Combined BRAFV600E-positive Melanocytic Lesions With Large Epithelioid Cells Lacking BAP1 Expression and Conventional Nevomelanocytes. <i>American Journal of Surgical Pathology</i> , 2013, 37, 193-199. | 3.7 | 89 |
| 465 | Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 61-65. | 3.7 | 289 |
| 466 | Chromogenic <i>in situ</i> Hybridization is a Reliable Alternative to Fluorescence <i>in situ</i> Hybridization for Diagnostic Testing of 1p and 19q Loss in Paraffin-Embedded Gliomas. <i>Brain Pathology</i> , 2013, 23, 311-318. | 4.1 | 21 |
| 467 | Immunohistochemical Analysis of BRAFV600E Expression of Primary and Metastatic Melanoma and Comparison With Mutation Status and Melanocyte Differentiation Antigens of Metastatic Lesions. <i>American Journal of Surgical Pathology</i> , 2013, 37, 413-420. | 3.7 | 99 |
| 468 | Sensitivity of Malignant Peripheral Nerve Sheath Tumor Cells to TRAIL Is Augmented by Loss of NF1 through Modulation of MYC/MAD and Is Potentiated by Curcumin through Induction of ROS. <i>PLoS ONE</i> , 2013, 8, e57152. | 2.5 | 28 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 469 | A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1. PLoS ONE, 2013, 8, e59773. | 2.5 | 39 |
| 470 | Nbn and Atm Cooperate in a Tissue and Developmental Stage-Specific Manner to Prevent Double Strand Breaks and Apoptosis in Developing Brain and Eye. PLoS ONE, 2013, 8, e69209. | 2.5 | 17 |
| 471 | Abstract LB-80: ATRX loss refines the classification of anaplastic glioma and is a favorable prognostic marker.., 2013,, . | | 1 |
| 472 | Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO Journal, 2012, 31, 2629-2647. | 7.8 | 110 |
| 473 | Addressing Diffuse Glioma as a Systemic Brain Disease With Single-Cell Analysis. Archives of Neurology, 2012, 69, 523. | 4.5 | 148 |
| 474 | Application of a BRAF V600E Mutation-specific Antibody for the Diagnosis of Hairy Cell Leukemia. American Journal of Surgical Pathology, 2012, 36, 1796-1800. | 3.7 | 135 |
| 475 | Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma. American Journal of Surgical Pathology, 2012, 36, 844-850. | 3.7 | 177 |
| 476 | High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood, 2012, 120, 2700-2703. | 1.4 | 589 |
| 477 | Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. International Journal of Oncology, 2012, 40, 2058-62. | 3.3 | 23 |
| 478 | Enzymatic assay for quantitative analysis of (d)-2-hydroxyglutarate. Acta Neuropathologica, 2012, 124, 883-891. | 7.7 | 58 |
| 479 | BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood, 2012, 120, e28-e34. | 1.4 | 199 |
| 480 | K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathologica, 2012, 124, 439-447. | 7.7 | 799 |
| 481 | LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathologica, 2012, 124, 875-881. | 7.7 | 115 |
| 482 | Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 2012, 22, 425-437. | 16.8 | 1,551 |
| 483 | Long-Term Outcome After Radiotherapy in Patients With Atypical and Malignant Meningiomasâ€”Clinical Results in 85 Patients Treated in a Single Institution Leading to Optimized Guidelines for Early Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 859-864. | 0.8 | 128 |
| 484 | Bone marrow biopsies of patients with hematopoietic and lymphoid disorders â€” epidemiology, chromosomal aberrations and molecular pathology. Pathology Research and Practice, 2012, 208, 510-517. | 2.3 | 2 |
| 485 | IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure: the Journal of the British Epilepsy Association, 2012, 21, 194-197. | 2.0 | 123 |
| 486 | Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. Cell, 2012, 148, 59-71. | 28.9 | 743 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 487 | Nestin Expression Identifies Ependymoma Patients with Poor Outcome. <i>Brain Pathology</i> , 2012, 22, 848-860. | 4.1 | 40 |
| 488 | Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. <i>Nature</i> , 2012, 482, 226-231. | 27.8 | 2,129 |
| 489 | Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 488-491. | 1.2 | 51 |
| 490 | Clonal Analysis in Recurrent Astrocytic, Oligoastrocytic and Oligodendroglial Tumors Implicates IDH1- Mutation as Common Tumor Initiating Event. <i>PLoS ONE</i> , 2012, 7, e41298. | 2.5 | 43 |
| 491 | Impaired Pten Expression in Human Malignant Peripheral Nerve Sheath Tumours. <i>PLoS ONE</i> , 2012, 7, e47595. | 2.5 | 49 |
| 492 | Dissecting the genomic complexity underlying medulloblastoma. <i>Nature</i> , 2012, 488, 100-105. | 27.8 | 765 |
| 493 | 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. <i>International Journal of Cancer</i> , 2012, 131, 766-768. | 5.1 | 74 |
| 494 | Epigenetically mediated downregulation of the differentiation-promoting chaperon protein CRABP2 in astrocytic gliomas. <i>International Journal of Cancer</i> , 2012, 131, 1963-1968. | 5.1 | 18 |
| 495 | No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. <i>Journal of Neuro-Oncology</i> , 2012, 109, 15-22. | 2.9 | 66 |
| 496 | Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 515-527. | 7.7 | 66 |
| 497 | Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. <i>Acta Neuropathologica</i> , 2012, 123, 841-852. | 7.7 | 77 |
| 498 | CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. <i>Acta Neuropathologica</i> , 2012, 123, 853-860. | 7.7 | 130 |
| 499 | Detection of 2-Hydroxyglutarate in Formalin-Fixed Paraffin-Embedded Glioma Specimens by Gas Chromatography/Mass Spectrometry. <i>Brain Pathology</i> , 2012, 22, 26-31. | 4.1 | 49 |
| 500 | The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. <i>EMBO Molecular Medicine</i> , 2012, 4, 38-51. | 6.9 | 81 |
| 501 | Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. <i>Acta Neuropathologica</i> , 2012, 123, 223-233. | 7.7 | 204 |
| 502 | Brain metastases: pathobiology and emerging targeted therapies. <i>Acta Neuropathologica</i> , 2012, 123, 205-222. | 7.7 | 163 |
| 503 | Abstract 3687: An integrative genomics approach identifies distinct molecular and epigenetic subgroups of pediatric glioblastoma. <i>Cancer Research</i> , 2012, 72, 3687-3687. | 0.9 | 15 |
| 504 | Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma. <i>PLoS ONE</i> , 2012, 7, e33449. | 2.5 | 120 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 505 | Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase. PLoS ONE, 2012, 7, e47663. | 2.5 | 42 |
| 506 | Mutation specific antibodies: tool or dinosaur?. Oncotarget, 2012, 3, 907-908. | 1.8 | 6 |
| 507 | Clinical neuropathology practice news 2-2012: BRAF V600E testing. , 2012, 31, 64-66. | | 12 |
| 508 | Abstract 3240: The Wnt secretion factor Evi/Wls/Gpr177 promotes glioma tumorigenesis. , 2012, , . | | 1 |
| 509 | Abstract 4736: N-myc downstream regulated gene 1: A novel mediator of hypoxia-driven chemoresistance in glioblastoma. , 2012, , . | | 0 |
| 510 | Abstract 1424: KCNJ2 comprises a marker of poor prognosis and a therapeutic target in non-WNT/non-SHH medulloblastoma. , 2012, , . | | 1 |
| 511 | Abstract 1432: The heterogeneous genomic landscape of posterior fossa ependymoma. , 2012, , . | | 0 |
| 512 | BRAF V600E Mutations in Multiple Myeloma: Clinical and Therapeutic Implications. Blood, 2012, 120, 4040-4040. | 1.4 | 1 |
| 513 | Adult Medulloblastoma Comprises Three Major Molecular Variants. Journal of Clinical Oncology, 2011, 29, 2717-2723. | 1.6 | 215 |
| 514 | An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature, 2011, 478, 197-203. | 27.8 | 1,514 |
| 515 | Improved Correlation of the Neuropathologic Classification According to Adapted World Health Organization Classification and Outcome After Radiotherapy in Patients With Atypical and Anaplastic Meningiomas. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1415-1421. | 0.8 | 59 |
| 516 | The p53 Tumor Suppressor Is Stabilized by Inhibitor of Growth 1 (ING1) by Blocking Polyubiquitination. PLoS ONE, 2011, 6, e21065. | 2.5 | 36 |
| 517 | Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation. Histopathology, 2011, 58, 1167-1172. | 2.9 | 13 |
| 518 | The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations. Brain Pathology, 2011, 21, 74-87. | 4.1 | 150 |
| 519 | Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma. Cancer Cell, 2011, 20, 143-157. | 16.8 | 494 |
| 520 | Identification of diagnostic serum protein profiles of glioblastoma patients. Journal of Neuro-Oncology, 2011, 102, 71-80. | 2.9 | 49 |
| 521 | Prognostic stratification of gliomatosis cerebri by IDH1R132H and INA expression. Journal of Neuro-Oncology, 2011, 105, 219-224. | 2.9 | 36 |
| 522 | Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathologica, 2011, 121, 241-252. | 7.7 | 124 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 523 | R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1 α upregulation in adult glioma. <i>Acta Neuropathologica</i> , 2011, 121, 279-281. | 7.7 | 67 |
| 524 | Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. <i>Acta Neuropathologica</i> , 2011, 121, 397-405. | 7.7 | 914 |
| 525 | Oncogenic FAM131B \rightarrow BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. <i>Acta Neuropathologica</i> , 2011, 121, 763-774. | 7.7 | 211 |
| 526 | Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. <i>Acta Neuropathologica</i> , 2011, 122, 11-19. | 7.7 | 445 |
| 527 | A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. <i>Acta Neuropathologica</i> , 2011, 122, 637-650. | 7.7 | 77 |
| 528 | Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?. <i>Radiation Oncology</i> , 2011, 6, 115. | 2.7 | 99 |
| 529 | Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas. <i>Glia</i> , 2011, 59, 1200-1204. | 4.9 | 44 |
| 530 | Molecular signatures classify astrocytic gliomas by IDH1 mutation status. <i>International Journal of Cancer</i> , 2011, 128, 1095-1103. | 5.1 | 75 |
| 531 | Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. <i>International Journal of Cancer</i> , 2011, 128, 1981-1988. | 5.1 | 44 |
| 532 | Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?. <i>Clinical Cancer Research</i> , 2011, 17, 4588-4599. | 7.0 | 179 |
| 533 | FSTL5 Is a Marker of Poor Prognosis in Non-WNT/Non-SHH Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3852-3861. | 1.6 | 143 |
| 534 | Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF- β 2. <i>Clinical Cancer Research</i> , 2011, 17, 4296-4308. | 7.0 | 290 |
| 535 | The efficacy of bipolar and multipolar radiofrequency ablation of lung neoplasms – results of an ablate and resect study. <i>European Journal of Cardio-thoracic Surgery</i> , 2011, 39, 968-973. | 1.4 | 38 |
| 536 | Abstract 4699: Oncogenic fusion genes resulting from 7q34 deletions constitute a novel mechanism of MAPK pathway activation in pilocytic astrocytoma. , 2011, , . | | 0 |
| 537 | Abstract 3453: Induction of differentiation in high-risk ependymoma stem-like cells by treatment with the HDAC inhibitor Vorinostat. , 2011, , . | | 0 |
| 538 | Presence of Alternative Lengthening of Telomeres Mechanism in Patients With Glioblastoma Identifies a Less Aggressive Tumor Type With Longer Survival. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 729-736. | 1.7 | 76 |
| 539 | Medulloblastoma Harbor Somatic Mitochondrial DNA Mutations in the D-loop Region. <i>Journal of Pediatric Hematology/Oncology</i> , 2010, 32, 156-159. | 0.6 | 14 |
| 540 | Application of Mutant IDH1 Antibody to Differentiate Diffuse Glioma From Nonneoplastic Central Nervous System Lesions and Therapy-induced Changes. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1199-1204. | 3.7 | 108 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 541 | IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody. <i>Haematologica</i> , 2010, 95, 1797-1798. | 3.5 | 13 |
| 542 | Chemoradiotherapy of Newly Diagnosed Glioblastoma With Intensified Temozolomide. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 670-676. | 0.8 | 50 |
| 543 | Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. <i>Acta Neuropathologica</i> , 2010, 120, 253-260. | 7.7 | 129 |
| 544 | Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. <i>Acta Neuropathologica</i> , 2010, 120, 261-267. | 7.7 | 47 |
| 545 | Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. <i>Acta Neuropathologica</i> , 2010, 120, 707-718. | 7.7 | 719 |
| 546 | Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. <i>Journal of Neuro-Oncology</i> , 2010, 98, 11-19. | 2.9 | 31 |
| 547 | Increased levels of 2-Hydroxyglutarate in AML patients with IDH1 R132H and IDH2 R140Q mutations. <i>European Journal of Haematology</i> , 2010, 85, 457-459. | 2.2 | 39 |
| 548 | Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing. <i>Leukemia Research</i> , 2010, 34, 1091-1093. | 0.8 | 18 |
| 549 | PCR- and Restriction Endonuclease-Based Detection of IDH1 Mutations. <i>Brain Pathology</i> , 2010, 20, 298-300. | 4.1 | 58 |
| 550 | Characterization of R132H Mutation-Specific IDH1 Antibody Binding in Brain Tumors. <i>Brain Pathology</i> , 2010, 20, 245-254. | 4.1 | 463 |
| 551 | The 4q12 Amplicon in Malignant Peripheral Nerve Sheath Tumors: Consequences on Gene Expression and Implications for Sunitinib Treatment. <i>PLoS ONE</i> , 2010, 5, e11858. | 2.5 | 25 |
| 552 | Defective p53 antiangiogenic signaling in glioblastoma. <i>Neuro-Oncology</i> , 2010, 12, 894-907. | 1.2 | 14 |
| 553 | Molecular Staging of Intracranial Ependymoma in Children and Adults. <i>Journal of Clinical Oncology</i> , 2010, 28, 3182-3190. | 1.6 | 210 |
| 554 | TP53 Mutation Is Frequently Associated With CTNNB1 Mutation or MYCN Amplification and Is Compatible With Long-Term Survival in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 5188-5196. | 1.6 | 100 |
| 555 | Role of LIM and SH3 Protein 1 (LASP1) in the Metastatic Dissemination of Medulloblastoma. <i>Cancer Research</i> , 2010, 70, 8003-8014. | 0.9 | 62 |
| 556 | Inositol-requiring enzyme 1 α is a key regulator of angiogenesis and invasion in malignant glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 15553-15558. | 7.1 | 262 |
| 557 | HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth. <i>Clinical Cancer Research</i> , 2010, 16, 3240-3252. | 7.0 | 175 |
| 558 | Carbon ion radiation therapy for high-risk meningiomas. <i>Radiotherapy and Oncology</i> , 2010, 95, 54-59. | 0.6 | 75 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 559 | Adult and Pediatric Medulloblastomas Are Genetically Distinct and Require Different Algorithms for Molecular Risk Stratification. <i>Journal of Clinical Oncology</i> , 2010, 28, 3054-3060. | 1.6 | 136 |
| 560 | Abstract 31: Subgroup-specific molecular alterations may explain the tremendous clinical heterogeneity of intracranial ependymoma. , 2010, , . | | 0 |
| 561 | Abstract 1178: Identification of a novel BRAF fusion partner in pilocytic astrocytoma. , 2010, , . | | 0 |
| 562 | Histone Deacetylase 8 in Neuroblastoma Tumorigenesis. <i>Clinical Cancer Research</i> , 2009, 15, 91-99. | 7.0 | 335 |
| 563 | Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. <i>Neuro-Oncology</i> , 2009, 11, 122-131. | 1.2 | 117 |
| 564 | Reversal of P-glycoprotein-Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3. <i>Cancer Research</i> , 2009, 69, 416-421. | 0.9 | 89 |
| 565 | Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array. <i>Neuro-Oncology</i> , 2009, 11, 803-818. | 1.2 | 43 |
| 566 | Epigenetic Silencing of Death Receptor 4 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Gliomas. <i>Clinical Cancer Research</i> , 2009, 15, 5457-5465. | 7.0 | 52 |
| 567 | Somatic mitochondrial mutations in pilocytic astrocytoma. <i>Cancer Genetics and Cytogenetics</i> , 2009, 192, 30-35. | 1.0 | 23 |
| 568 | Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 229-238. | 2.8 | 24 |
| 569 | Novel oncogene amplifications in tumors from a family with Li-Fraumeni syndrome. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 558-568. | 2.8 | 13 |
| 570 | Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. <i>Acta Neuropathologica</i> , 2009, 117, 457-464. | 7.7 | 106 |
| 571 | Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. <i>Acta Neuropathologica</i> , 2009, 117, 445-456. | 7.7 | 88 |
| 572 | Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. <i>Acta Neuropathologica</i> , 2009, 118, 401-405. | 7.7 | 255 |
| 573 | Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. <i>Acta Neuropathologica</i> , 2009, 118, 469-474. | 7.7 | 1,020 |
| 574 | Monoclonal antibody specific for IDH1 R132H mutation. <i>Acta Neuropathologica</i> , 2009, 118, 599-601. | 7.7 | 380 |
| 575 | Decreased expression of the active subunit of the cystine/glutamate antiporter xCT is associated with loss of heterozygosity of 1p in oligodendroglial tumours WHO grade II. <i>Histopathology</i> , 2009, 54, 241-247. | 2.9 | 4 |
| 576 | Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas. <i>Modern Pathology</i> , 2009, 22, 1263-1271. | 5.5 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 577 | <i>RASSF1A</i> , <i>BLU</i> , <i>NORE1A</i> , <i>PTEN</i> and <i>MGMT</i> Expression and Promoter Methylation in Gliomas and Glioma Cell Lines and Evidence of Deregulated Expression of <i>de novo</i> DNMTs. <i>Brain Pathology</i> , 2009, 19, 279-292. | 4.1 | 47 |
| 578 | Molecular Pathology of Oligodendroglial Tumors. <i>Recent Results in Cancer Research</i> , 2009, 171, 25-49. | 1.8 | 16 |
| 579 | Intraoperative Radiofrequency Ablation of Lung Metastases and Histologic Evaluation. <i>Annals of Thoracic Surgery</i> , 2009, 87, 379-384. | 1.3 | 29 |
| 580 | NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide. <i>Journal of Clinical Oncology</i> , 2009, 27, 5874-5880. | 1.6 | 743 |
| 581 | Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network. <i>Journal of Clinical Oncology</i> , 2009, 27, 5743-5750. | 1.6 | 534 |
| 582 | The Inhibitor of Growth 1 (ING1) Is Involved in Trichostatin A-Induced Apoptosis and Caspase 3 Signaling in p53-Deficient Glioblastoma Cells. <i>Oncology Research</i> , 2009, 18, 469-480. | 1.5 | 17 |
| 583 | Hereditary Tumor Syndromes and Gliomas. <i>Recent Results in Cancer Research</i> , 2009, 171, 83-102. | 1.8 | 40 |
| 584 | The Inhibitor of Growth 1 (ING1) Proteins Suppress Angiogenesis and Differentially Regulate Angiopoietin Expression in Glioblastoma Cells. <i>Oncology Research</i> , 2009, 18, 95-105. | 1.5 | 11 |
| 585 | Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death. <i>Journal of Neuro-Oncology</i> , 2008, 86, 23-30. | 2.9 | 12 |
| 586 | Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II. <i>Journal of Molecular Histology</i> , 2008, 39, 553-560. | 2.2 | 10 |
| 587 | Accumulation of genomic aberrations during clinical progression of medulloblastoma. <i>Acta Neuropathologica</i> , 2008, 116, 383-390. | 7.7 | 23 |
| 588 | Analysis of the IDH1 codon 132 mutation in brain tumors. <i>Acta Neuropathologica</i> , 2008, 116, 597-602. | 7.7 | 910 |
| 589 | The Evolution of Our Understanding on Glioma. <i>Brain Pathology</i> , 2008, 18, 455-463. | 4.1 | 23 |
| 590 | Detection of methylation in promoter sequences by melting curve analysis-based semiquantitative real time PCR. <i>BMC Cancer</i> , 2008, 8, 61. | 2.6 | 54 |
| 591 | Yes and PI3K Bind CD95 to Signal Invasion of Glioblastoma. <i>Cancer Cell</i> , 2008, 13, 235-248. | 16.8 | 281 |
| 592 | The flavonoid kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3566-3574. | 4.1 | 92 |
| 593 | EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. <i>Neuro-Oncology</i> , 2008, 10, 946-957. | 1.2 | 71 |
| 594 | Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme. <i>Neuro-Oncology</i> , 2007, 9, 291-297. | 1.2 | 49 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 595 | Long-term survival with glioblastoma multiforme. Brain, 2007, 130, 2596-2606. | 7.6 | 748 |
| 596 | Association between fluorine-18 ¹⁸ F-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas. Journal of Neurosurgery, 2007, 106, 633-637. | 1.6 | 25 |
| 597 | Combined 1p/19q Loss in Oligodendroglial Tumors: Predictive or Prognostic Biomarker?. Clinical Cancer Research, 2007, 13, 6933-6937. | 7.0 | 131 |
| 598 | Occurrence of a Spinal Anaplastic Pilocytic Astrocytoma and a Supratentorial PNET in an Adolescent. Journal of Pediatric Hematology/Oncology, 2007, 29, 832-835. | 0.6 | 2 |
| 599 | Expression of PACAP and glutamate transporter proteins in satellite oligodendrocytes of the human CNS. Regulatory Peptides, 2007, 142, 52-59. | 1.9 | 25 |
| 600 | Onconase induces caspase-independent cell death in chemoresistant neuroblastoma cells. Cancer Letters, 2007, 250, 107-116. | 7.2 | 45 |
| 601 | MMP-13, p53 in the Progression of Malignant Peripheral Nerve Sheath Tumors. Neoplasia, 2007, 9, 671-677. | 5.3 | 53 |
| 602 | DNA hypermethylation and Aberrant Expression of the <i>EMP3</i> Gene at 19q13.3 in Human Gliomas. Brain Pathology, 2007, 17, 363-370. | 4.1 | 47 |
| 603 | Granulomatous tissue response in germinoma, a diagnostic pitfall in endoscopic biopsy. Neuropathology, 2007, 27, 127-132. | 1.2 | 23 |
| 604 | Intracranial Thermo-therapy using Magnetic Nanoparticles Combined with External Beam Radiotherapy: Results of a Feasibility Study on Patients with Glioblastoma Multiforme. Journal of Neuro-Oncology, 2007, 81, 53-60. | 2.9 | 632 |
| 605 | Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. Journal of Neuro-Oncology, 2007, 82, 187-192. | 2.9 | 76 |
| 606 | Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells. Clinical and Experimental Metastasis, 2007, 24, 57-66. | 3.3 | 38 |
| 607 | A new clinico-pathological classification system for mesial temporal sclerosis. Acta Neuropathologica, 2007, 113, 235-244. | 7.7 | 321 |
| 608 | Cellular localization of pituitary adenylate cyclase-activating peptide (PACAP) following traumatic brain injury in humans. Acta Neuropathologica, 2007, 113, 683-693. | 7.7 | 24 |
| 609 | Decreased Expression of Glutamate Transporters in Astrocytes after Human Traumatic Brain Injury. Journal of Neurotrauma, 2006, 23, 1518-1528. | 3.4 | 124 |
| 610 | A role for β -melanocyte-stimulating hormone in human body-weight regulation. Cell Metabolism, 2006, 3, 141-146. | 16.2 | 171 |
| 611 | A Rapid and Sensitive Protocol for Competitive Reverse Transcriptase (cRT) PCR Analysis of Cellular Genes. Brain Pathology, 2006, 8, 13-18. | 4.1 | 42 |
| 612 | NF2 Mutations in Secretory and Other Rare Variants of Meningiomas. Brain Pathology, 2006, 16, 15-19. | 4.1 | 56 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 613 | 45- YEAR-OLD MALE WITH SYMPTOMATIC MASS IN THE FRONTAL LOBE. Brain Pathology, 2006, 16, 89-90. | 4.1 | 5 |
| 614 | The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. Journal of Neuro-Oncology, 2006, 78, 7-14. | 2.9 | 409 |
| 615 | Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 428-432. | 6.4 | 91 |
| 616 | Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9. Cancer, 2006, 107, 1365-1372. | 4.1 | 28 |
| 617 | Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. International Journal of Cancer, 2006, 119, 792-800. | 5.1 | 66 |
| 618 | Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis, 2006, 27, 664-671. | 2.8 | 89 |
| 619 | Chromosome 22 tiling-path array-CGH analysis identifies germ-line- and tumor-specific aberrations in patients with glioblastoma multiforme. Genes Chromosomes and Cancer, 2005, 44, 161-169. | 2.8 | 30 |
| 620 | Mutation analysis of DKK1 and in vivo evidence of predominant p53-independent DKK1 function in gliomas. Acta Neuropathologica, 2005, 109, 314-320. | 7.7 | 12 |
| 621 | PIK3CA mutations in glioblastoma multiforme. Acta Neuropathologica, 2005, 109, 639-642. | 7.7 | 85 |
| 622 | Pilocytic astrocytoma presenting as primary diffuse leptomeningeal gliomatosis: report of a unique case and review of the literature. Acta Neuropathologica, 2005, 110, 306-311. | 7.7 | 22 |
| 623 | Alterations of cell cycle regulators in gliomatosis cerebri. Journal of Neuro-Oncology, 2005, 72, 115-122. | 2.9 | 28 |
| 624 | Assessment of tumor cell invasion factors in gliomatosis cerebri. Journal of Neuro-Oncology, 2005, 73, 109-115. | 2.9 | 13 |
| 625 | Estimating cancer survival and clinical outcome based on genetic tumor progression scores. Bioinformatics, 2005, 21, 2438-2446. | 4.1 | 46 |
| 626 | The transcription factor Ets-1 is expressed in human amniochorionic membranes and is up-regulated in term and preterm premature rupture of membranes. Journal of Perinatal Medicine, 2005, 33, 314-9. | 1.4 | 6 |
| 627 | Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. International Journal of Oncology, 2005, 27, 1029. | 3.3 | 26 |
| 628 | Laser-assisted microdissection, techniques and applications in pathology (Review). International Journal of Molecular Medicine, 2005, 15, 763. | 4.0 | 7 |
| 629 | Molecular Genetic Analysis of Oligodendroglial Tumors. Journal of Neuropathology and Experimental Neurology, 2005, 64, 10-14. | 1.7 | 49 |
| 630 | Patients with High-Grade Gliomas Harboring Deletions of Chromosomes 9p and 10q Benefit from Temozolomide Treatment. Neoplasia, 2005, 7, 883-893. | 5.3 | 55 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 631 | Brain slice invasion model reveals genes differentially regulated in glioma invasion. Biochemical and Biophysical Research Communications, 2005, 336, 1227-1233. | 2.1 | 26 |
| 632 | Absence of Immunoglobulin Class Switch in Primary Lymphomas of the Central Nervous System. American Journal of Pathology, 2005, 166, 1773-1779. | 3.8 | 47 |
| 633 | Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors. Acta Neuropathologica, 2004, 107, 159-168. | 7.7 | 50 |
| 634 | Molecular pathogenesis of oligodendroglial tumors. Journal of Neuro-Oncology, 2004, 70, 161-181. | 2.9 | 99 |
| 635 | Pathology and molecular genetics of oligodendroglial tumors. Journal of Molecular Medicine, 2004, 82, 638-655. | 3.9 | 44 |
| 636 | Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors. Human Mutation, 2004, 23, 134-146. | 2.5 | 97 |
| 637 | Fine mapping of chromosome 22q tumor suppressor gene candidate regions in astrocytoma. International Journal of Cancer, 2004, 108, 839-844. | 5.1 | 26 |
| 638 | No ING1 mutations in human brain tumours but reduced expression in high malignancy grades of astrocytoma. International Journal of Cancer, 2004, 109, 476-479. | 5.1 | 32 |
| 639 | Pdgfr- α in 1p/19q LOH oligodendrogliomas. International Journal of Cancer, 2004, 112, 1081-1082. | 5.1 | 10 |
| 640 | Subclassification of Nerve Sheath Tumors by Gene Expression Profiling. Brain Pathology, 2004, 14, 258-264. | 4.1 | 42 |
| 641 | Ligands for PPAR γ and RAR Cause Induction of Growth Inhibition and Apoptosis in Human Glioblastomas. Journal of Neuro-Oncology, 2003, 65, 107-118. | 2.9 | 52 |
| 642 | Analysis of TP53 and PTEN in gliomatosis cerebri. Acta Neuropathologica, 2003, 105, 529-536. | 7.7 | 29 |
| 643 | Chromosomal region 15q21.1 is a frequent target of allelic imbalance in advanced breast carcinomas. International Journal of Cancer, 2003, 106, 74-77. | 5.1 | 21 |
| 644 | No preferential loss of paternal 19q alleles in oligodendroglial tumors. Annals of Neurology, 2003, 54, 256-258. | 5.3 | 10 |
| 645 | Differential Concentration-Dependent Effects of Prolonged Norepinephrine Infusion on Intraparenchymal Hemorrhage and Cortical Contusion in Brain-Injured Rats. Journal of Neurotrauma, 2003, 20, 1327-1337. | 3.4 | 4 |
| 646 | Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy (Review). International Journal of Oncology, 2003, 23, 857. | 3.3 | 13 |
| 647 | Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Research, 2003, 63, 1602-7. | 0.9 | 617 |
| 648 | Genetic Alterations Commonly Found in Diffusely Infiltrating Cerebral Gliomas Are Rare or Absent in Pleomorphic Xanthoastrocytomas. Journal of Neuropathology and Experimental Neurology, 2002, 61, 1092-1099. | 1.7 | 53 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 649 | Impact of Genotype and Morphology on the Prognosis of Glioblastoma. Journal of Neuropathology and Experimental Neurology, 2002, 61, 321-328. | 1.7 | 184 |
| 650 | Genetic Signature of Oligoastrocytomas Correlates with Tumor Location and Denotes Distinct Molecular Subsets. American Journal of Pathology, 2002, 161, 313-319. | 3.8 | 171 |
| 651 | Decreased hemispheric Aquaporin-4 is linked to evolving brain edema following controlled cortical impact injury in rats. Neuroscience Letters, 2002, 324, 105-108. | 2.1 | 121 |
| 652 | The SRCR/SID region of DMBT1 defines a complex multi-allele system representing the major basis for its variability in cancer. Genes Chromosomes and Cancer, 2002, 35, 242-255. | 2.8 | 39 |
| 653 | Rare mutations of the DMBT1 gene in human astrocytic gliomas. Oncogene, 2002, 21, 5956-5959. | 5.9 | 24 |
| 654 | Mutational analysis of INI1 in sporadic human brain tumors. Acta Neuropathologica, 2001, 101, 479-482. | 7.7 | 31 |
| 655 | Indications for a tumor suppressor gene at 22q11 involved in the pathogenesis of ependymal tumors and distinct from hSNF5/INI1. Acta Neuropathologica, 2001, 102, 69-74. | 7.7 | 50 |
| 656 | Analysis of the TSC2 gene in human medulloblastoma. Acta Neuropathologica, 2001, 102, 380-384. | 7.7 | 7 |
| 657 | Subtyping of oligo-astrocytic tumours by comparative genomic hybridization. Journal of Pathology, 2001, 194, 81-87. | 4.5 | 55 |
| 658 | Comparative analysis of the NF2, TP53, PTEN, KRAS, NRAS and HRAS genes in sporadic and radiation-induced human meningiomas. International Journal of Cancer, 2001, 94, 218-221. | 5.1 | 80 |
| 659 | Early expression of glutamate transporter proteins in ramified microglia after controlled cortical impact injury in the rat. Glia, 2001, 35, 167-179. | 4.9 | 117 |
| 660 | TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. Journal of Neuro-Oncology, 2001, 52, 263-272. | 2.9 | 39 |
| 661 | Cloning and characterization of the human GFRA2 locus and investigation of the gene in Hirschsprung disease. Human Genetics, 2001, 108, 409-415. | 3.8 | 17 |
| 662 | Loss of NF1 Alleles Distinguish Sporadic from NF1-Associated Pilocytic Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2001, 60, 917-920. | 1.7 | 113 |
| 663 | Malignant transformation of a gangliocytoma/ganglioglioma into a glioblastoma multiforme: a molecular genetic analysis. Journal of Neurosurgery, 2001, 95, 138-142. | 1.6 | 58 |
| 664 | Clonal Analysis in Glioblastoma with Epithelial Differentiation. Brain Pathology, 2001, 11, 39-43. | 4.1 | 23 |
| 665 | Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes and Cancer, 2000, 29, 16-25. | 2.8 | 13 |
| 666 | Molecular analysis of the TSC1 and TSC2 tumour suppressor genes in sporadic glial and glioneuronal tumours. Human Genetics, 2000, 107, 350-356. | 3.8 | 41 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 667 | Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation. Journal of Neurology, 2000, 247, 455-460. | 3.6 | 57 |
| 668 | Comprehensive Allelotype and Genetic Analysis of 466 Human Nervous System Tumors. Journal of Neuropathology and Experimental Neurology, 2000, 59, 544-558. | 1.7 | 137 |
| 669 | Long survival and therapeutic responses in patient histologically disparate high-grade gliomas demonstrating chromosome 1p loss. Journal of Neurosurgery, 2000, 92, 983-990. | 1.6 | 133 |
| 670 | Low Frequency of SV40, JC and BK Polyomavirus Sequences in Human Medulloblastomas, Meningiomas and Ependymomas. Brain Pathology, 2000, 10, 85-92. | 4.1 | 81 |
| 671 | Chromosomal Imbalances in Brain Metastases of Solid Tumors. Brain Pathology, 2000, 10, 395-401. | 4.1 | 60 |
| 672 | Mapping of the chromosome 19 qâ€arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes and Cancer, 2000, 29, 16-25. | 2.8 | 74 |
| 673 | Clonal Origin of Recurrent Meningiomas. Brain Pathology, 1999, 9, 645-650. | 4.1 | 20 |
| 674 | A case history of glioma progression. Acta Neuropathologica, 1999, 97, 525-532. | 7.7 | 27 |
| 675 | Quantitative analysis of NF1 and OMGP gene transcripts in sporadic gliomas, sporadic meningiomas and neurofibromatosis type 1-associated plexiform neurofibromas. Acta Neuropathologica, 1999, 97, 547-551. | 7.7 | 7 |
| 676 | Analysis of theMEN1 gene in sporadic pituitary adenomas. , 1999, 188, 168-173. | | 37 |
| 677 | Molecular Genetic Analysis of Ependymal Tumors. American Journal of Pathology, 1999, 155, 627-632. | 3.8 | 226 |
| 678 | Identification of Subgroups of High-grade Oligodendroglial Tumors by Comparative Genomic Hybridization. Journal of Neuropathology and Experimental Neurology, 1999, 58, 606-612. | 1.7 | 83 |
| 679 | Common Regions of Deletion on Chromosome 22q12.3-q13.1 and 22q13.2 In Human Astrocytomas Appear Related To Malignancy Grade. Journal of Neuropathology and Experimental Neurology, 1999, 58, 881-885. | 1.7 | 57 |
| 680 | Molecular Genetic Analysis as a Tool for Evaluating Stereotactic Biopsies of Glioma Specimens. Journal of Neuropathology and Experimental Neurology, 1999, 58, 40-45. | 1.7 | 13 |
| 681 | Differential patterns of molecular genetic alterations define subsets among glioblastomas and oligoastrocytomas. Neuropathology, 1998, 18, 145-153. | 1.2 | 2 |
| 682 | PTEN mutations in gliomas and glioneuronal tumors. Oncogene, 1998, 16, 2259-2264. | 5.9 | 300 |
| 683 | A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene, 1998, 16, 2403-2406. | 5.9 | 92 |
| 684 | Expression of theATM gene is significantly reduced in sporadic breast carcinomas. , 1998, 78, 306-309. | | 37 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 685 | Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses. <i>International Journal of Cancer</i> , 1998, 79, 640-644. | 5.1 | 153 |
| 686 | Analysis of a polymorphism in the tuberous sclerosis (TSC2) gene does not predispose to schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1998, 248, 314-315. | 3.2 | 2 |
| 687 | Clonality of multiple meningiomas. <i>Journal of Neurosurgery</i> , 1997, 86, 853-858. | 1.6 | 77 |
| 688 | p53 Accumulation Promotes Dephosphorylation and Proteolytic Cleavage of Retinoblastoma Protein in Human Malignant Glioma Cells. <i>Cellular Physiology and Biochemistry</i> , 1997, 7, 304-311. | 1.6 | 6 |
| 689 | Molecular Genetic Evidence for Subtypes of Oligoastrocytomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 1098-1104. | 1.7 | 219 |
| 690 | A Novel Splice Site Associated Polymorphism in the Tuberous Sclerosis 2 (TSC2) Gene May Predispose to the Development of Sporadic Gangliogliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 806-810. | 1.7 | 29 |
| 691 | Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative 'tumor progression' locus. <i>Oncogene</i> , 1997, 14, 611-616. | 5.9 | 109 |
| 692 | DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3â€“26.1 is deleted in malignant brain tumours. <i>Nature Genetics</i> , 1997, 17, 32-39. | 21.4 | 423 |
| 693 | Tuberous sclerosis-like lesions in epileptogenic human neocortex lack allelic loss at the TSC1 and TSC2 regions. <i>Acta Neuropathologica</i> , 1997, 93, 93-96. | 7.7 | 26 |
| 694 | Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast carcinoma. , 1997, 74, 322-325. | | 22 |
| 695 | A Polymerase Chain Reaction-based Assay for the Rapid Detection of Gene Amplification in Human Tumors. <i>Diagnostic Molecular Pathology</i> , 1996, 5, 147-150. | 2.1 | 27 |
| 696 | Lack of prognostic relevance of alterations in the epidermal growth factor receptorâ€™transforming growth factor-Î± pathway in human astrocytic gliomas. <i>Journal of Neurosurgery</i> , 1996, 85, 634-641. | 1.6 | 69 |
| 697 | The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. <i>Cancer Genetics and Cytogenetics</i> , 1996, 88, 136-140. | 1.0 | 57 |
| 698 | A Model for the Molecular Pathogenesis of Astrocytic Gliomas. , 1996, , 173-186. | | 0 |
| 699 | Evidence for Subarachnoid Spread in the Development of Multiple Meningiomas. <i>Brain Pathology</i> , 1995, 5, 11-14. | 4.1 | 33 |
| 700 | THE CHROMOSOME 19q GLIOMA TUMOR SUPPRESSOR GENE. <i>Journal of Neuropathology and Experimental Neurology</i> , 1995, 54, 439. | 1.7 | 1 |
| 701 | Shared Allelic Losses on Chromosomes 1p and 19q Suggest a Common Origin of Oligodendroglioma and Oligoastrocytoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 1995, 54, 91-95. | 1.7 | 306 |
| 702 | Chromosome 19q Deletions in Human Gliomas Overlap Telomeric to D19S219 and May Target a 425 kb Region Centromeric to D19S112. <i>Journal of Neuropathology and Experimental Neurology</i> , 1995, 54, 622-626. | 1.7 | 39 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 703 | Molecular pathways in the formation of gliomas. <i>Glia</i> , 1995, 15, 328-338. | 4.9 | 227 |
| 704 | Hereditary Tumor Syndromes of the Nervous System: Overview and Rare Syndromes. <i>Brain Pathology</i> , 1995, 5, 145-151. | 4.1 | 53 |
| 705 | MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. <i>Human Molecular Genetics</i> , 1994, 3, 1841-1845. | 2.9 | 96 |
| 706 | Deletion mapping of chromosome 19 in human gliomas. <i>International Journal of Cancer</i> , 1994, 57, 676-680. | 5.1 | 90 |
| 707 | The retinoblastoma gene is involved in malignant progression of astrocytomas. <i>Annals of Neurology</i> , 1994, 36, 714-721. | 5.3 | 211 |
| 708 | Deletions on the long arm of chromosome 17 in pilocytic astrocytoma. <i>Acta Neuropathologica</i> , 1993, 86, 81-85. | 7.7 | 93 |
| 709 | Subsets of Glioblastoma Multiforme Defined by Molecular Genetic Analysis. <i>Brain Pathology</i> , 1993, 3, 19-26. | 4.1 | 597 |
| 710 | MOLECULAR GENETIC ALTERATIONS IN PEDIATRIC BRAIN STEM GLIOMAS. <i>Journal of Neuropathology and Experimental Neurology</i> , 1993, 52, 267. | 1.7 | 2 |
| 711 | Molecular Genetics of Pediatric Brain Stem Gliomas. Application of PCR Techniques to Small and Archival Brain Tumor Specimens. <i>Journal of Neuropathology and Experimental Neurology</i> , 1993, 52, 507-515. | 1.7 | 91 |
| 712 | Comparative Study of p53 Gene and Protein Alterations in Human Astrocytic Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 1993, 52, 31-38. | 1.7 | 203 |
| 713 | Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 1992, 77, 295-301. | 1.6 | 185 |
| 714 | Central neurocytoma: histopathological variants and therapeutic approaches. <i>Journal of Neurosurgery</i> , 1992, 76, 32-37. | 1.6 | 210 |
| 715 | Desmoplastic cerebral astrocytomas of infancy: A histopathologic, immunohistochemical, ultrastructural, and molecular genetic study. <i>Human Pathology</i> , 1992, 23, 1402-1409. | 2.0 | 73 |
| 716 | Location of N-methyl-N-2-nitro-N-nitrosoguanidine-induced gastrointestinal tumors correlates with thiol distribution. <i>Carcinogenesis</i> , 1983, 4, 879-883. | 2.8 | 35 |